U.S. patent application number 16/997760 was filed with the patent office on 2021-08-26 for llp2a-bisphosphonate conjugates for osteoporosis treatment.
This patent application is currently assigned to The Regents of the University of California. The applicant listed for this patent is The Regents of the University of California. Invention is credited to Kit S. Lam, Nancy Lane, Ruiwu Liu, Wei Yao.
Application Number | 20210261612 16/997760 |
Document ID | / |
Family ID | 1000005553371 |
Filed Date | 2021-08-26 |
United States Patent
Application |
20210261612 |
Kind Code |
A1 |
Lam; Kit S. ; et
al. |
August 26, 2021 |
LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT
Abstract
The present invention provides compounds and pharmaceutical
compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated
with a bisphosphonate drug, e.g. Alendronate. The compounds and
pharmaceutical compositions of the present invention are useful in
the treatment of osteoporosis and for the promotion of bone growth
due to their specificity for the .alpha..sub.4.beta..sub.1 integrin
on mesenchymal stem cells and for the surface of bone.
Inventors: |
Lam; Kit S.; (Davis, CA)
; Liu; Ruiwu; (Sacramento, CA) ; Yao; Wei;
(El Dorado Hills, CA) ; Lane; Nancy;
(Hillsborough, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The Regents of the University of California |
Oakland |
CA |
US |
|
|
Assignee: |
The Regents of the University of
California
Oakland
CA
|
Family ID: |
1000005553371 |
Appl. No.: |
16/997760 |
Filed: |
August 19, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16700067 |
Dec 2, 2019 |
|
|
|
16997760 |
|
|
|
|
15387380 |
Dec 21, 2016 |
10494401 |
|
|
16700067 |
|
|
|
|
14806398 |
Jul 22, 2015 |
9561256 |
|
|
15387380 |
|
|
|
|
13820362 |
Oct 28, 2013 |
9119884 |
|
|
PCT/US2012/021909 |
Jan 19, 2012 |
|
|
|
14806398 |
|
|
|
|
PCT/US2011/050381 |
Sep 2, 2011 |
|
|
|
13820362 |
|
|
|
|
61379643 |
Sep 2, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/661 20130101;
A61K 31/00 20130101; C07F 9/02 20130101; A61K 38/06 20130101; A61K
38/08 20130101; C07K 7/06 20130101; C07K 5/0821 20130101; A61K
38/00 20130101; C07K 5/0817 20130101; A61K 31/663 20130101; A61K
47/64 20170801; A61K 47/548 20170801; C07K 5/1016 20130101; C07K
5/101 20130101; A61K 31/66 20130101; A61K 38/10 20130101; C07K
5/1019 20130101; A61K 35/28 20130101 |
International
Class: |
C07K 5/097 20060101
C07K005/097; A61K 31/663 20060101 A61K031/663; C07K 7/06 20060101
C07K007/06; A61K 31/66 20060101 A61K031/66; C07F 9/02 20060101
C07F009/02; A61K 31/00 20060101 A61K031/00; A61K 38/08 20060101
A61K038/08; A61K 31/661 20060101 A61K031/661; A61K 38/10 20060101
A61K038/10; C07K 5/09 20060101 C07K005/09; C07K 5/103 20060101
C07K005/103; C07K 5/107 20060101 C07K005/107; A61K 47/64 20060101
A61K047/64; A61K 47/54 20060101 A61K047/54; C07K 5/11 20060101
C07K005/11; A61K 35/28 20060101 A61K035/28; A61K 38/06 20060101
A61K038/06 |
Goverment Interests
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED
RESEARCH AND DEVELOPMENT
[0002] This invention was made with Government support under Grant
No. AR057515 awarded by the National Institutes of Health. The
Government has certain rights in this invention.
Claims
1. A pharmaceutical composition comprising a compound of Formula I:
##STR00055## or a salt or isomer thereof, and a pharmaceutically
acceptable excipient, wherein each R.sup.1 and R.sup.2 is
independently selected from the group consisting of H, halogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, and C.sub.1-6 haloalkyl; R.sup.3
is selected from the group consisting of H, C.sub.1-6 alkyl and
C.sub.3-8 cycloalkyl; X is selected from the group consisting of O,
S and NH; Y is selected from the group consisting of O and NH;
alternatively, R.sup.1 or R.sup.2 is combined with Y and the atoms
to which they are attached to form a 5-membered heteroaryl ring; Z
is a peptide having 3-20 independently selected amino acids,
wherein at least one amino acid is selected from the group
consisting of an unnatural amino acid and a D-amino acid; L is a
linker; D has the formula: ##STR00056## wherein R.sup.4 is selected
from the group consisting of H, OH and halogen; R.sup.5 is selected
from the group consisting of H and C.sub.1-6 alkyl; and subscripts
m, n and q are each independently from 0 to 2; and subscript t is
from 1 to 6.
2. The pharmaceutical composition of claim 1, wherein the portion
of the compound bonded to Z has a formula selected from the group
consisting of: ##STR00057##
3. The pharmaceutical composition of claim 1, wherein the portion
of the compound bonded to Z has a formula selected from the group
consisting of: ##STR00058##
4. The pharmaceutical composition of claim 1, wherein the portion
of the compound bonded to Z has a formula selected from the group
consisting of: ##STR00059##
5. The pharmaceutical composition of claim 1, wherein the portion
of the compound bonded to Z has a formula selected from the group
consisting of: ##STR00060##
6. The pharmaceutical composition of claim 1, wherein the portion
of the compound bonded to Z is a formula selected from the group
consisting of: ##STR00061##
7. The pharmaceutical composition of claim 1, wherein the portion
of the compound bonded to Z has the formula: ##STR00062##
8. The pharmaceutical composition of claim 1, wherein peptide Z has
the formula: --X.sub.AA1--X.sub.AA2--X.sub.AA3--(X.sub.AA4).sub.p--
wherein X.sub.AA1 is selected from the group consisting of a
hydrophobic amino acid and derivatives of lysine, homolysine (Hly),
ornithine (Orn) and .alpha.,.gamma.-diaminobutyric acid (Dbu);
X.sub.AA2 is a negatively charged amino acid; X.sub.AA3 is a
hydrophobic amino acid; X.sub.AA4 is selected from the group
consisting of a naturally-occurring amino acid, an unnatural amino
acid, and a D-amino acid; and subscript p is 0 or 1.
9. The pharmaceutical composition of claim 8, wherein X.sub.AA1 is
lysine-A38 (Lys38); X.sub.AA2 is .alpha.-aminohexanedioic acid
(Aad); X.sub.AA3 is a D-amino acid; and subscript p is 0.
10. The pharmaceutical composition of claim 1, wherein peptide Z is
selected from the group consisting of -Lys38-Aad-D-Phe,
-Lys38-Aad-Ach, -Lys38-Aad-D-Nal-2, -Lys38-Aad-Ile, -Lys38-Aad-Val,
and -Lys38-Aad-Leu.
11. The pharmaceutical composition of claim 1, wherein peptide Z is
-Lys38-Aad-Ach.
12. The pharmaceutical composition of claim 1, wherein linker L
comprises at least one of N-(8-amino-3,6-dioxa-octyl)succinamic
acid (EBES) and polyethylene glycol (PEG).
13. The pharmaceutical composition of claim 1, wherein linker L is
selected from the group consisting of: ##STR00063## ##STR00064##
##STR00065## wherein k is from 0 to 6.
14. (canceled)
15. The pharmaceutical composition of claim 1, wherein D has the
formula selected from the group consisting of: ##STR00066##
16. The pharmaceutical composition of claim 1, having the compound
has a formula selected from the group consisting of: ##STR00067##
##STR00068## ##STR00069##
17. (canceled)
18. A method of treating osteoporosis or low bone mass, comprising
administering to a subject in need thereof, a therapeutically
effective amount of a pharmaceutical composition of claim 1.
19. A method of promoting bone growth, comprising administering to
a subject in need thereof, a therapeutically effective amount of a
pharmaceutical composition of claim 1.
20. (canceled)
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 16/700,067, filed Feb. 2, 2019, which is a
continuation of U.S. patent application Ser. No. 15/387,380, filed
Dec. 21, 2016, issued as U.S. Pat. No. 10,494,401, which is a
continuation of U.S. patent application Ser. No. 14/806,398, filed
Jul. 22, 2015, issued as U.S. Pat. No. 9,561,256, which is a
continuation of U.S. patent application Ser. No. 13/820,362, filed
Oct. 28, 2013, issued as U.S. Pat. No. 9,119,884, which is a
National Stage entry under 35 U.S.C. .sctn. 371 of International
Application No. PCT/US2012/021909, filed Jan. 19, 2012, which is a
continuation-in-part of International Application No.
PCT/US2011/050381, filed Sep. 2, 2011, which claims priority to
U.S. Provisional Application No. 61/379,643, filed Sep. 2, 2010,
each of which is incorporated in its entirety herein for all
purposes.
REFERENCE TO A "SEQUENCE LISTING"
[0003] The Sequence Listing written in file
SequenceListing_070772-206415US-1208489.txt created on Nov. 27,
2019, 9,005 bytes, machine format IBM-PC, MS-Windows operating
system, in accordance with 37 C.F.R. .sctn..sctn. 1.821-1.825, is
hereby incorporated by reference in its entirety for all
purposes.
BACKGROUND OF THE INVENTION
[0004] Osteoporosis is a disease of increased bone fragility that
results from estrogen deficiency and aging. It is a major public
health problem with nearly 50% of Caucasian women and 25% of
Caucasian men at risk for an osteoporotic fracture in their
lifetimes (Publication from National Osteoporosis Foundation).
Accordingly, osteoporosis represents a significant health
concern.
[0005] A decrease in the number of mesenchymal stem cells (MSCs) in
the bone marrow with aging leads to reduced osteogenesis and may be
the most important factor responsible for reduced bone formation
and increase bone fragility (Heersche, J. N., C. G. Bellows, and Y.
Ishida, J Prosthet Dent, 1998, 79(1): p. 14-6.; Ettinger, M. P.,
Arch Intern Med, 2003. 163(18): p. 2237-46). Currently, nearly all
of the treatments for osteoporosis reduce bone loss by decreasing
osteoclastic bone resorption and thereby preventing the further
breakdown of bone. Importantly, this class of drugs does not
restore the lost bone structure. Therapeutic modalities that target
bone formation by either increasing the number and or the activity
of osteoblasts may be a more attractive approach that will enhance
bone formation and promote bone regeneration. Although bone
regeneration by induction of osteogenesis from MSCs is a rational
strategy to treat osteoporosis, systemic infusions of MSCs in vivo
has failed to promote an osteogenic response in bone due to the
inability of MSCs to migrate to the bone surface which is a major
clinical problem for MSC transplantation (Gao, J., et al., Cells
Tissues Organs, 2001. 169(1): p. 12-20; Meyerrose, T. E., et al.,
Stem Cells, 2007, 25(1): p. 220-7). In addition, engraftment of the
MSCs requires donor ablation using chemotherapy and/or radiation
which may result in concomitant damage to endogenous mesenchymal
cells (Bacigalupo, A., Best Pract Res Clin Haematol, 2004, 17(3):
p. 387-99).
[0006] Cell adhesion is a process by which cells associate with
each other, migrate towards a specific target, or localize within
the extracellular matrix. Cell adhesion constitutes one of the
fundamental mechanisms underlying numerous biological phenomena.
Investigations into the molecular basis for cell adhesion have
revealed that various cell surface macromolecules, collectively
known as cell adhesion molecules or receptors, mediate cell-cell
and cell-matrix interactions. For example, members of the integrin
family of cell surface receptors mediate cell-cell and cell-matrix
interactions and regulate cell motility, migration, survival, and
proliferation (Hynes, Cell, 69: 11-25 (1992); Hynes, Cell,
1110:673-687 (2002)). Integrins are non-covalent heterodimeric
complexes consisting of two subunits, .alpha. and .beta.. There are
at least 18 different .alpha. subunits and at least 8 different
.beta. subunits.
[0007] Mesenchymal stem cells within the bone marrow have a
multi-lineage potential and represent a mixture of precursors for
mesenchymal-derived cell types including osteoblasts, chondrocytes
and adipocytes (Owen, M. et al., Ciba Found Symp, 1988, 136: p.
42-60; Bruder, S. P., et al., J Cell Biochem, 1994, 56(3): p.
283-94; Prockop, D. J., Science, 1997, 276(5309): p. 71-4). Bone
cells at all maturation stages rely heavily on cell-matrix and
cell-cell interactions (Mukherjee, S., et al., J Clin Invest, 2008,
118(2): p. 491-504; Grzesik, W. J. and P. G. Robey, J Bone Miner
Res, 1994, 9(4): p. 487-96; Vukicevic, S., et al., Cell, 1990,
63(2): p. 437-45; Mbalaviele, G., et al., J Bone Miner Res, 2006,
21(12): p. 1821-7). Bone marrow is the site where the committed
osteoblast progenitors reside, and the osteogenic differentiation
is the default pathway for MSC lineage commitment (Halleux, C., et
al., J Musculoskelet Neuronal Interact, 2001, 2(1): p. 71-6;
Muraglia, A., et al., J Cell Sci, 2000, 113 (Pt 7): p. 1161-6).
Mobilization of the osteoblastic progenitors to the bone surface is
a critical step for the osteoblasts to mature and form mineralized
tissue (Adams, G. B., et al., Nature, 2006, 439(7076): p. 599-603;
Chen, X. D., et al., J Bone Miner Res, 2007, 22(12): p. 1943-56).
Once the osteoblastic progenitors are "directed" to the bone
surface, they synthesize a range of proteins including osteocalcin,
osteopontin, bone sialoprotein, osteonectin, collagen-I and
fibronectin that will further enhance the adhesion and maturation
of osteoblasts (Gronthos, S., et al., Periodontol 2000, 2006, 41:
p. 188-95; Gronthos, S., et al., Bone, 2001, 28(2): p. 174-81;
Gronthos, S., et al., J Bone Miner Res, 1997, 12(8): p. 1189-97).
These interactions are largely mediated by transmembrane integrin
receptors that primarily utilize an arginine-glycine-aspartate
(RGD) sequence to identify and bind to specific ligands. MSCs
express integrins al, 2, 3, 4, 6, 11, CD51 (integrin .alpha.V), and
CD29 (integrins .beta.1) (Brooke, G., et al., Stem Cells Dev,
2008). Integrins .alpha..sub.1.beta..sub.1,
.alpha..sub.2.beta..sub.1, .alpha..sub.v.beta..sub.1,
.alpha..sub.v.beta..sub.5, .alpha..sub.5.beta..sub.1 and
.alpha..sub.4.beta..sub.1 are reported to be expressed in the
osteoblastic cells (Grzesik, W. J. and Robey, P. G., J Bone Miner
Res, 1994, 9(4): p. 487-96; Gronthos, S., et al., Bone, 2001,
28(2): p. 174-81; Gronthos, S., et al., J Bone Miner Res, 1997.
12(8): p. 1189-97; Cowles, E. A., L. L. Brailey, and G. A.
Gronowicz, J Biomed Mater Res, 2000, 52(4): p. 725-37).
Overexpression of .alpha..sub.4 Integrin on MSCs has been reported
to increase homing of the MSCs to bone (Mukherjee, S., et al., J
Clin Invest, 2008, 118(2): p. 491-504).
[0008] Bisphosphonates are widely used for the treatment of
osteoporosis. This class of drugs is also used as a "vehicle" for
delivering bone-targeted drugs to osseous tissue as prodrugs based
on their biphosphonic moiety. Bisphosphonates have been used to
deliver sustained release diclofenac, a non-steroidal
anti-inflammatory drug to bone in rats (Hirabayashi, H., et al., J
Control Release, 2001, 70(1-2): p. 183-91). The bisphosphonate dose
needed for this drug-delivery purpose is usually 10-100 fold lower
than the doses needed for the treatments of osteoporosis,
hypocalcaemia, Paget's disease or metastatic bone cancer.
[0009] It is well-understood that bone formation is beneficial for
the treatment of a wide variety of disparate disorders in mammals
including simple aging, bone degeneration and osteoporosis,
fracture healing, fusion or arthrodesis, osteogenesis imperfecta,
etc., as well as for successful installation of various medical
orthopedic and periodontal implants such as screws, rods, titanium
cage for spinal fusion, hip joints, knee joint, ankle joints,
shoulder joints, dental plates and rods, etc.
[0010] Increasing bone mineralization to treat conditions
characterized at least in part by increased bone resorption, such
as osteopenia, bone fractures, osteoporosis, arthritis, tumor
metastases, Paget's disease and other metabolic bone disorders,
using cathepsin K inhibitors and TGF-beta binding proteins, etc.,
are well-known as shown by U.S. Publication No. 2004/0235728 to
Selwyn Aubrey Stoch, published Nov. 25, 2004, and Mary E. Brunkow
et al., U.S. Pat. No. 6,489,445 and U.S. Publication No.
2004/0009535, published Jan. 15, 2004. In the Brunkow '445 patent
and '535 publication, the TGF-beta binding proteins include Sost
polypeptide (full length and short peptide) antibodies that
interfere with the interaction between the TGF-beta binding protein
sclerostin and a TGF-beta superfamily member, and in particular a
bone morphogenic protein. In the Brunkow '445 Patent a novel family
of human TGF-beta binding proteins and nucleic acids encoding them
are recited. The protein binds to at least human bone morphogenic
protein-5 and human bone morphogenic protein-6. The aforementioned
diseases are due to a systemic loss of bone mineral and thus the
administration of the antibody therapeutic is for the systemic
(whole body) increase in bone mineral density.
[0011] U.S. Publication No. 2006/0165799, published Jul. 27, 2006,
teaches a bone-filling composition for stimulating bone-formation
and bone-consolidation comprising biocompatible calcium sulfate and
viscous biopolymers. The composition is intended to be administered
into the missing part of injured bone without diffusing to
surrounding organs.
[0012] U.S. Publication No. 2005/025604, published Nov. 17, 2005,
shows induction of bone formation by mechanically inducing an
increase in osteoblast activity and elevating systemic blood
concentration of a bone anabolic agent, including optionally
elevating systemic blood concentration of an antiresorptive
agent.
[0013] U.S. Pat. No. 7,576,175, issued Aug. 18, 2009, shows
.alpha..sub.4.beta..sub.1 integrin ligands that display high
binding affinity, specificity, and stability. The ligands comprise
a peptide having n independently selected amino acids, wherein at
least one amino acid is an unnatural amino acid or a D-amino acid,
and wherein n is an integer of from 3 to 20.
[0014] U.S. Publication No. 2010/0021379, published Jan. 28, 2010,
shows antibody conjugates comprising a targeting agent covalently
attached to an antibody or fragment thereof. The targeting agent
includes a ligand comprising a peptide or peptidomimetic specific
for an integrin receptor such as the .alpha..sub.462 .sub.1
integrin.
[0015] What is needed in the art is new compositions and methods
for treating osteoporosis and promoting bone growth. Surprisingly,
the present invention meets these and other needs.
BRIEF SUMMARY OF THE INVENTION
[0016] In a first embodiment, the present invention provides a
compound of Formula I:
##STR00001##
wherein Formula I each R.sup.1 and R.sup.2 is independently
selected from H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, and
C.sub.1-6 haloalkyl. R.sup.3 is selected from H, C.sub.1-6 alkyl
and C.sub.3-8 cycloalkyl. X is selected from O, S and NH. Y is
selected from O and NH. Alternatively, R.sup.1 or R.sup.2 is
combined with Y and the atoms to which they are attached to form a
5-membered heteroaryl ring. Z is a peptide having 3-20
independently selected amino acids, wherein at least one amino acid
is selected from an unnatural amino acid and a D-amino acid. L is a
linker. D is a bisphosphonate drug. Subscripts m, n and q are each
independently from 0 to 2. Also included are salts and isomers of
the compounds of Formula I.
[0017] In a second embodiment, the present invention provides a
pharmaceutical composition including a compound of the present
invention and a pharmaceutically acceptable excipient.
[0018] In a third embodiment, the present invention provides a
method of treating osteoporosis, including administering to a
subject in need thereof, a therapeutically effective amount of a
compound of the present invention.
[0019] In a fourth embodiment, the present invention provides a
method of promoting bone growth, including administering to a
subject in need thereof, a therapeutically effective amount of a
compound of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] FIG. 1 shows beta-glucuronidase distribution in bone
24-hours following huMSCs transplantation in NOD/SCID/MSPVII mice.
Three-month-old MSPVII mice received a single intravenous injection
of either of PBS, huMSC (5.times.10.sup.5), huMSC+LLP2A, or
huMSC+LLP2A-Ale. The mice were sacrificed 24 hours later. Following
sacrifice, lumbar vertebral bodies were harvested and frozen in
Optimal Cutting Temperature embedding media. The sections were
stained using naphthol-AS-BI-.beta.-Dglucuronide (GUSB) as a
substrate. Human MSCs, as showed by GUSB+ red stains (black arrows)
were seen accumulated in bone marrow, adjacent to both trabecular
and periosteal bone surfaces in huMSCs+LLP2A-Ale group.
[0021] FIG. 2A-C show LLP2A-Ale increases trabecular bone formation
three weeks following huMSCs transplantation in NOD/SCID/MSPVII
mice. FIG. 2A: Bone turnover markers measured from the serum. FIG.
2B: Representative histological sections from the lumber vertebral
trabecular bone from PBS, MSC, MSC+LLP2A or MSC+LLP2A-Ale-treated
groups. Alizarin red was given at 20 mg/kg at baseline and calcein
(10 mg/kg) was given subcutaneously 7 days and 2 days before the
mice were sacrificed. FIG. 2C: Surface-based bone histomorphometry
performed at the 5.sup.th lumbar vertebral bodies three weeks after
the injection and MSC transplantation. ObS/BS, osteoblast surface;
MAR, mineral apposition rate; BFR/BS, bone surface-based bone
formation rate. *,p<0.05 versus PBS; **,p<0.01 versus PBS.
Data are represented as Mean.+-.SD.
[0022] FIG. 3A-B show LLP2A-Ale increases cortical bone formation
three weeks following huMSCs transplantation in NOD/SCID/MSPVII
mice. FIG. 3A: Representative cross-sections of the mid-femur from
PBS, MSC, MSC+LLP2A, and MSC+LLP2A-Ale-treated groups are shown.
Alizarin red was given at 20 mg/kg at baseline (prior to the
injection of the study compound) and calcein (10 mg/kg) was given
subcutaneously 7 days and 2 days before the mice were sacrificed.
FIG. 3B: Surface-based bone histomorphometry, performed at the
endocortical surface (Ec) and the periosteal surface (Ps) three
weeks after the injections of either MSCs or LLP2A-Ale, is shown. *
and ** are as defined above for FIG. 2A-C.
[0023] FIG. 4A-C show LLP2A-Ale increases cancellous bone mass
through increasing the thickness of the trabeculae. In vivo microCT
scans were performed on the right distal femurs at baseline (basal)
and repeated after 4 weeks. FIG. 4A-B: Representative 3-dimensional
thickness maps from microCT scanning of the cancellous bone from
the distal femur metaphysic are shown at baseline (A) and after 4
weeks (B). The width of the trabeculae is color coded, the
blue-green color represents thin trabeculae and yellow-red color
represents thick trabeculae. Representative 3-dimensional thickness
maps from each group are shown in the lower panel. FIG. 4C:
Percentage changes from baseline (left panel), maximum load (center
panel), and maximum stress (right panel) with the different
treatments are shown. BV/TV refers to cancellous bone volume/total
tissue volume fraction; Tb.Th refers to trabecular thickness.
Maximum load and stress were measured at the 6.sup.th lumbar
vertebral body. * and ** are as defined above for FIG. 2A-C.
[0024] FIG. 5A-C show LLP2A-Ale increases cancellous bone formation
in young "normal" mice. FIG. 5A: Bone turnover markers measured
from the serum for Runx2 and Bglap1 are shown. FIG. 5B: Bone
turnover markers measured from the serum for P1NP, osteocalcin, and
CTX-1 are shown. FIG. 5C: Surface-based bone histomorphometry,
performed on the right distal femurs, is shown. ObS/BS, MAR,
BFR/BS, *, and ** are as defined above for FIG. 2A-C.
[0025] FIG. 6A-B show LLP2A-Ale increases cortical bone formation
in young normal mice. FIG. 6A: Representative cross-sections of the
mid-femur from mice injected with either PBS, LLP2A, Ale, or
LLP2A-Ale (10 ng or 250 ng/mouse) are shown. Alizarin red was given
at 20 mg/kg at baseline (prior to the injection of the study
compound) and calcein (10 mg/kg) was given subcutaneously 7 days
and 2 days before the mice were sacrificed. FIG. 6B: Surface-based
bone histomorphometry, performed at the endocortical surface (Ec)
and the periosteal surface (Ps) four weeks after the injections, is
shown. * and ** are as defined above for FIG. 2A-C.
[0026] FIG. 7 shows osteogenic cells had high affinity for
LLP2A-Ale. Mouse MSCs were purchased from Invitrogen (Cat
#S1502-100), cultured in osteogenic medium for 7 days and incubated
with rainbow beads for one hour. The purple beads that displayed
LLP2A, the ligand with high affinity and specificity against
.alpha.4.beta.1, were covered with layers of cells (green arrows).
Original magnification 10.times. on the right and 20.times. on the
left of the top panel.
[0027] FIG. 8 shows Beta-glucuronidase distribution in various
tissues 24-hours following huMSCs transplantation in
NOD/SCID/MSPVII mice.
[0028] FIG. 9 shows LLP2A-Ale increases proliferating cell
populations adjacent to bone surfaces. Decalcified 4.sup.th lumbar
vertebral sections were double-stained with alkaline phosphatase
(blue staining) and BrdU (Bromodeoxyuridine) to monitor the
proliferating cells (brown staining, yellow arrows).
[0029] FIG. 10A-C show the synthetic approach of LLP2A-Ale. FIG.
10A: Synthesis of 4-[(N'-2-methylphenyl)ureido]phenylacetic acid
(UPA). FIG. 10B: Solid phase synthesis of LLP2A-Lys(D-Cys). FIG.
10C: Preparation of LLP2A-Ale through conjugating LLP2A-Lys(D-Cys)
with Ale-Mal.
[0030] FIG. 11 shows the synthesis of LLP2A-Ale (1).
[0031] FIG. 12 shows exemplary compounds of the present
invention.
[0032] FIG. 13A-B show LLP2A-Ale increases MSC osteoblast
maturation, function and migration without affecting their
chondrogenic or adipogenic potentials.
[0033] FIG. 14A-C show retention of the transplanted huMSCs in bone
3-weeks following co-injection in mice with LLP2A-Ale and huMSCs
(FIG. 14A), and increased osteoblasts and osteocytes at cortical
(FIG. 14B) and trabecular (FIG. 14C) bong regions in lumbar
vertebral bodies (LVB) 3 weeks following co-injection in mice with
LLP2A-Ale and GFP-labeled huMSCs.
[0034] FIG. 15 shows LLP2A-Ale treatment increased osteoblast
surface and formed bridges between adjacent trabeculae in
immunocompetent mice (129SvJ).
[0035] FIG. 16A-B show bone formation rates on the endocortical
surfaces of the tibial shafts were increased in groups that had
LLP2A component (P<0.05) in immunocompetent mice (129SvJ).
[0036] FIG. 17 shows LLP2A-Ale prevents age-related trabecular bone
after peak bone acquisition in C57BL/6 mice.
[0037] FIG. 18A-B show LLP2A-Ale increases bone formation
parameters at the trabecular DF (P<0.05) in C57BL/6 mice.
[0038] FIG. 19A-B show LLP2A-Ale increases bone formation
parameters at the trabecular bone surfaces in the lumbar vertebral
bodies (LVB) in C57BL/6 mice.
[0039] FIG. 20 shows a scheme of 10-week-old ovariectomized (OVX)
mice treated with PBS, Ale, LLP2, LLP2A-Ale or PTH 2-weeks after
ovariectomy.
[0040] FIG. 21 depicts histomorphometric analyses of the 5th lumbar
vertebral bodies after LLP2A-Ale treatment of 10-week-old
ovariectomized (OVX) mice, showing increases in osteoblast numbers,
activities and bone formation rate/bone surface (BFR/BS)
post-treatment. Analyses included trabecular bone area (%),
osteoblast surface (Ob/BS), mineralizing surface (MS/BS) activities
and BFR/BS (P<0.05).
[0041] FIG. 22 shows LLP2A-Ale treatment increases osteoblast
numbers in the lumbar vertebral bodies (LVB) of 10-week-old
ovariectomized (OVX) mice. Representative fluorescent images from
the trabecular bone at the 5th LVB (Top panel: white arrowheads
illustrate osteoblasts; Bottom panel: yellow arrows illustrate
double labeled trabecular bone surfaces).
[0042] FIG. 23 depicts histomorphometry analyses of the right
mid-femurs included bone formation at the endosteal (Ec) or
periosteal (Ps.) bone surfaces, and cortical bone thickness of
10-week-old ovariectomized (OVX) mice. Increases in endocortical
bone formation from OVX were observed in the LLP2A-Ale and PTH
treated mice, however cortical bone thickness and maximum stress
were not significantly altered by OVX, Ale, and LLP2A, one single
IV injection of LLPAle or four weeks of PTH treatment. Three-point
bending was performed on left femurs to obtain maximum stress of
the femurs.
[0043] FIG. 24 shows representative fluorescent images from the
mid-femur sections of 10-week-old ovariectomized (OVX) mice and
increases in endocortical bone formation were observed in the
LLP2A-Ale and PTH treatments. Short yellow arrows illustrated
double labeled endocortical bone surfaces. (a, p<0.05 versus
Sham; b, P<0.05 vs. OVX+PBS, c, P<0.05 vs. OVX+LLP2A; d,
P<0.05 vs. OVX+Ale. Data are represented as Mean.+-.SD).
[0044] FIG. 25 shows the evaluation of the efficacy of LLP2A-Ale
and LLP2A-Ale (1) in their ability in guiding the mesenchymal stem
cells (MSC) to bone. We injected 2.times.105 mouse green
florescence labeled (GFP)-MSCs to 2-month-old (3-day experiment) or
to the 5-month-old (3-week experiment) C57BL/6 mice via I.V. tail
vein. LLP2A-Ale or LLP2A-Ale (1) were dissolved in 0.9% normal
saline and injected I.P. to the mice one hour after MSC at a final
solution of 0.9 nmol/mouse. Mice were sacrificed either at 3 days
or 3 weeks. Osteocalcin, a bone formation marker, was measured at
both 3 days and 3 weeks post-treatments. The lumbar vertebral
bodies from the 3-day treatment groups were frozen and sectioned
with cryostat. The sections were then stained with anti-GFP
antibody. The transplanted MSCs were stained in brown. We found
both LLP2A-Ale and LLP2A-Ale (1) significantly increased
osteocalcin levels at both three-days and three weeks following the
treatments. Transplanted MSCs were observed within bone marrow and
adjacent to the trabecular bone surfaces at three-days.
DETAILED DESCRIPTION OF THE INVENTION
I. GENERAL
[0045] The present invention provides compounds and pharmaceutical
compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated
with a bisphosphonate, e.g. Alendronate. The compounds and
pharmaceutical compositions of the present invention are useful for
the treatment of osteoporosis, the treatment of low bone mass, the
treatment of patient populations characterized by fractured or
injured bone, and for the promotion of bone growth due to their
specificity for the .alpha..sub.4.beta..sub.1 integrin on
mesenchymal stem cells and for the surface of bone.
II. DEFINITIONS
[0046] The abbreviations used herein have their conventional
meaning within the chemical and biological arts.
[0047] As used herein, the terms "Ale" or "Alen", refer to
Alendronate.
[0048] Where substituent groups are specified by their conventional
chemical formulae, written from left to right, they equally
encompass the chemically identical substituents that would result
from writing the structure from right to left, e.g., --CH.sub.2O--
is equivalent to --OCH.sub.2--.
[0049] As used herein, the terms "halo" or "halogen," by themselves
or as part of another substituent, mean, unless otherwise stated, a
fluorine, chlorine, bromine, or iodine atom.
[0050] As used herein, the term "alkyl" refers to a straight or
branched, saturated, aliphatic radical having the number of carbon
atoms indicated. For example, C.sub.1-C.sub.6 alkyl includes, but
is not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl,
iso-propyl, iso-butyl, sec-butyl, tert-butyl, etc.
[0051] As used herein, the term "haloalkyl" refers to alkyl as
defined above where some or all of the hydrogen atoms are
substituted with halogen atoms. For example, haloalkyl includes
trifluoromethyl, fluoromethyl, 1,2,3,4,5-pentafluoro-phenyl, etc.
The term "perfluoro" defines a compound or radical which has at
least two available hydrogens substituted with fluorine. For
example, perfluorophenyl refers to 1,2,3,4,5-pentafluorophenyl,
perfluoromethane refers to 1,1,1-trifluoromethyl, and
perfluoromethoxy refers to 1,1,1-trifluoromethoxy.
[0052] As used herein, the term "heteroalkyl" refers to an alkyl
group having from 1 to 3 heteroatoms such as N, O and S. Additional
heteroatoms can also be useful, including, but not limited to B,
Al, Si and P. The heteroatoms can also be oxidized, such as, but
not limited to, --S(O)-- and --S(O).sub.2--. For example,
heteroalkyl can include ethers, thioethers, alkyl-amines and
alkyl-thiols.
[0053] As used herein, the term "alkoxy" refers to alkyl with the
inclusion of an oxygen atom, for example, methoxy, ethoxy, etc.
[0054] As used herein, the term "aryl" refers to a monocyclic or
fused bicyclic, tricyclic or greater, aromatic ring assembly
containing 6 to 16 ring carbon atoms. For example, aryl may be
phenyl, benzyl or naphthyl, preferably phenyl. "Arylene" means a
divalent radical derived from an aryl group. Aryl groups can be
mono-, di- or tri-substituted by one, two or three radicals
selected from alkyl, alkoxy, aryl, hydroxy, halogen, cyano, amino,
amino-alkyl, trifluoromethyl, alkylenedioxy and
oxy-C.sub.2-C.sub.3-alkylene; all of which are optionally further
substituted, for instance as hereinbefore defined; or 1- or
2-naphthyl; or 1- or 2-phenanthrenyl. Alkylenedioxy is a divalent
substitute attached to two adjacent carbon atoms of phenyl, e.g.
methylenedioxy or ethylenedioxy. Oxy-C.sub.2-C.sub.3-alkylene is
also a divalent substituent attached to two adjacent carbon atoms
of phenyl, e.g. oxyethylene or oxypropylene. An example for
oxy-C.sub.2-C.sub.3-alkylene-phenyl is
2,3-dihydrobenzofuran-5-yl.
[0055] Preferred as aryl is phenyl or phenyl mono- or disubstituted
by alkyl, heteroalkyl, or halogen.
[0056] As used herein, the term "heteroaryl" refers to a monocyclic
or fused bicyclic or tricyclic aromatic ring assembly containing 5
to 16 ring atoms, where from 1 to 4 of the ring atoms are a
heteroatom. For example, heteroaryl includes pyridyl, indolyl,
indazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl,
benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl,
oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl,
thienyl, or any other radicals substituted, especially mono- or
di-substituted, by e.g. alkyl, nitro or halogen. Pyridyl represents
2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl. Thienyl
represents 2- or 3-thienyl. Quinolinyl represents preferably 2-, 3-
or 4-quinolinyl. Isoquinolinyl represents preferably 1-, 3- or
4-isoquinolinyl. Benzopyranyl, benzothiopyranyl represents
preferably 3-benzopyranyl or 3-benzothiopyranyl, respectively.
Thiazolyl represents preferably 2- or 4-thiazolyl, and most
preferred, 4-thiazolyl. Triazolyl is preferably 1-, 2- or
5-(1,2,4-triazolyl). Tetrazolyl is preferably 5-tetrazolyl.
[0057] Preferably, heteroaryl is oxazolyl, imidazolyl, pyridyl,
indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl,
tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl,
benzothiazolyl, benzofuranyl, isoquinolinyl, benzothienyl,
indazolyl, or any of the radicals substituted, especially mono- or
di-substituted.
[0058] Substituents for the aryl and heteroaryl groups are varied
and are selected from: -halogen, --OR', --OC(O)R', --NR'R'', --SR',
--R', --CN, --NO.sub.2, --CO.sub.2R', --CONR'R'', --C(O)R',
--OC(O)NR'R'', --NR''C(O)R', --NR''C(O).sub.2R',
--NR'--C(O)NR''R''', --NH--C(NH.sub.2).dbd.NH,
--NR'C(NH.sub.2).dbd.NH, --NH--C(NH.sub.2).dbd.NR', --S(O)R',
--S(O).sub.2R', --S(O).sub.2NR'R'', --N.sub.3, --CH(Ph).sub.2,
perfluoro(C.sub.1-C.sub.4)alkoxy, and
perfluoro(C.sub.1-C.sub.4)alkyl, in a number ranging from zero to
the total number of open valences on the aromatic ring system; and
where R', R'' and R''' are independently selected from hydrogen,
C.sub.1-C.sub.8 alkyl and heteroalkyl, unsubstituted aryl and
heteroaryl, (unsubstituted aryl)-(C.sub.1-C.sub.4)alkyl, and
(unsubstituted aryl)oxy-(C.sub.1-C.sub.4)alkyl.
[0059] As used herein, the term "cycloalkyl" refers to a saturated
or partially unsaturated, monocyclic, fused bicyclic or bridged
polycyclic ring assembly containing from 3 to 12 ring atoms, or the
number of atoms indicated. For example, C.sub.3-8cycloalkyl
includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and up
to cyclooctyl.
[0060] As used herein, each of the above terms (e.g., "alkyl,"
"aryl" and "heteroaryl") are meant to include both substituted and
unsubstituted forms of the indicated radical.
[0061] Substituents for the alkyl and heteroalkyl radicals
(including those groups often referred to as alkylene, alkenyl,
heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one
or more of a variety of groups selected from, but not limited to:
--OR', .dbd.O, .dbd.NR', .dbd.N--OR', --NR'R'', --SR', -halogen,
--SiR'R''R''', --OC(O)R', --C(O)R', --CO.sub.2R', --CONR'R'',
--OC(O)NR'R'', --NR''C(O)R', --NR'--C(O)NR''R''',
--NR''C(O).sub.2R', --NR--C(NR'R''R''').dbd.NR'''',
--NR--C(NR'R'').dbd.NR''', --S(O)R', --S(O).sub.2R',
--S(O).sub.2NR'R'', --NR(SO.sub.2)R', --CN and --NO.sub.2 in a
number ranging from zero to (2m'+1), where m' is the total number
of carbon atoms in such radical. R', R'', R''' and R'''' are each
independently selected from hydrogen, C.sub.1-C.sub.8 alkyl and
heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted
aryl)-(C.sub.1-C.sub.4)alkyl, and (unsubstituted
aryl)oxy-(C.sub.1-C.sub.4)alkyl. When a compound of the invention
includes more than one R group, for example, each of the R groups
is independently selected as are each R', R'', R''' and R''''
groups when more than one of these groups is present. When R' and
R'' are attached to the same nitrogen atom, they can be combined
with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
For example, --NR'R'' is meant to include, but not be limited to,
1-pyrrolidinyl and 4-morpholinyl. From the above discussion of
substituents, one of skill in the art will understand that the term
"alkyl" is meant to include groups including carbon atoms bound to
groups other than hydrogen groups, such as haloalkyl (e.g.,
--CF.sub.3 and --CH.sub.2CF.sub.3) and acyl (e.g., --C(O)CH.sub.3,
--C(O)CF.sub.3, --C(O)CH.sub.2OCH.sub.3, and the like).
[0062] As used herein, the term "peptide" refers to a compound made
up of a single chain of D- or L-amino acids or a mixture of D- and
L-amino acids joined by peptide bonds. Generally, peptides are
about 2 to about 50 amino acids in length. Preferably, the peptides
of the present invention are about 2 to about 25 amino acids in
length, more preferably 3 to 20 amino acids in length, and most
preferably 3 to 10 amino acids in length.
[0063] As used herein, the term "amino acid" refers to naturally
occurring, unnatural, and synthetic amino acids, as well as amino
acid analogs and amino acid mimetics that function in a manner
similar to the naturally occurring amino acids.
[0064] As used herein, the terms "naturally-occurring amino acids"
refer to those amino acids which are encoded by the genetic code,
as well as those amino acids that are later modified, e.g.,
hydroxyproline, .gamma.-carboxyglutamate and O-phosphoserine.
Naturally-occurring .alpha.-amino acids include, without
limitation, alanine (Ala), cysteine (Cys), aspartic acid (Asp),
glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine
(His), isoleucine (Ile), arginine (Arg), lysine (Lys), leucine
(Leu), methionine (Met), asparagine (Asn), proline (Pro), glutamine
(Gln), serine (Ser), threonine (Thr), valine (Val), tryptophan
(Trp), tyrosine (Tyr), and combinations thereof. Stereoisomers of a
naturally-occurring .alpha.-amino acids include, without
limitation, D-alanine (D-Ala), D-cysteine (D-Cys), D-aspartic acid
(D-Asp), D-glutamic acid (D-Glu), D-phenylalanine (D-Phe),
D-histidine (D-His), D-isoleucine (D-Ile), D-arginine (D-Arg),
D-lysine (D-Lys), D-leucine (D-Leu), D-methionine (D-Met),
D-asparagine (D-Asn), D-proline (D-Pro), D-glutamine (D-Gln),
D-serine (D-Ser), D-threonine (D-Thr), D-valine (D-Val),
D-tryptophan (D-Trp), D-tyrosine (D-Tyr), and combinations
thereof.
[0065] As used herein, the terms "unnatural amino acids" include,
without limitation, amino acid analogs, amino acid mimetics,
synthetic amino acids, N-substituted glycines, and N-methyl amino
acids in either the L- or D-configuration that function in a manner
similar to the naturally-occurring amino acids. Unnatural amino
acids" are not encoded by the genetic code and can, but do not
necessarily have the same basic structure as a naturally occurring
amino acid.
[0066] As used herein, the terms "amino acid analogs" refer to
compounds that have the same basic chemical structure as a
naturally occurring amino acid, i.e., an a carbon that is bound to
a hydrogen, a carboxyl group, an amino group, and an R group, e.g.,
homoserine, norleucine, methionine sulfoxide, methionine methyl
sulfonium. Such analogs have modified R groups (e.g., norleucine)
or modified peptide backbones, but retain the same basic chemical
structure as a naturally occurring amino acid.
[0067] As used herein, the terms "amino acid mimetics" refer to
chemical compounds that have a structure that is different from the
general chemical structure of an amino acid, but that function in a
manner similar to a naturally-occurring amino acid. Suitable amino
acid mimetics include, without limitation, .beta.-amino acids and
.gamma.-amino acids. In .beta.-amino acids, the amino group is
bonded to the .beta.-carbon atom of the carboxyl group such that
there are two carbon atoms between the amino and carboxyl groups.
In .gamma.-amino acids, the amino group is bonded to the
.gamma.-carbon atom of the carboxyl group such that there are three
carbon atoms between the amino and carboxyl groups. Suitable R
groups for .beta.- or .gamma.-amino acids include, but are not
limited to, side-chains present in naturally-occurring amino acids
and unnatural amino acids.
[0068] As used herein, the terms "N-substituted glycines" refer to
unnatural amino acids based on glycine, where an amino acid
side-chain is attached to the glycine nitrogen atom. Suitable amino
acid side-chains (e.g., R groups) include, but are not limited to,
side chains present in naturally-occurring amino acids and
side-chains present in unnatural amino acids such as amino acid
analogs.
[0069] Amino acids can be characterized by at least one of several
properties. For example, amino acids can be positively charged,
negatively charged, hydrophilic, or hydrophobic.
[0070] As used herein, the terms "positively charged amino acid"
refer to those amino acids having a basic or positively charged
side chain at pH values below the pKa, and include, but are not
limited to, Lys, Arg, HoArg, Agp, Agb, Dab, Dap and Orn and
stereoisomers thereof. Basic amino acids can generally be referred
to by the symbol "X.sup.+".
[0071] As used herein, the terms "negatively charged amino acid"
refer to those amino acids having an acidic or negatively charged
side chain at pH values above the pKa, and include, but are not
limited to, Asp, Glu, Aad, Bec and stereoisomers thereof. Acidic
amino acids can generally be referred to by the symbol "X.sup.-".
One of skill in the art will appreciate that other basic and acidic
amino acids are known in the art.
[0072] As used herein, the terms "neutrally charged amino acids"
refer to those amino acids having a neutrally charged side chain at
pH values equal to the pKa.
[0073] As used herein, the terms "hydrophilic amino acid" refer to
those amino acids having a polar and uncharged side chain and
include, but are not limited to, Asn, Ser, Thr, and Gln.
[0074] As used herein, the terms "hydrophobic amino acids" refer to
those amino acids having a hydrophobic side chain and include, but
are not limited to, Val, Leu, Ile, Met, and Phe. Preferably, the
hydrophobic amino acid is selected from proline, a proline analog,
and a stereoisomer thereof. Preferably, the proline analog is
hydroxyproline.
[0075] As used herein, the terms "D-amino acids" refer to the D
stereoisomer of an amino acid. The letters D and L are
conventionally used in the art to refer to the stereoisomers of an
amino acid. D-amino acids are those amino acids that could be
synthesized from the dextrorotary isomer of glyceraldehyde, i.e.
D-glyceraldehyde. Similarly, L-amino acids are those amino acids
that could be synthesized from the levorotary isomer of
glyceraldehyde, i.e. L-glyceraldehyde.
[0076] Amino acids may be referred to herein by either the commonly
known three letter symbols or by the one-letter symbols recommended
by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides,
likewise, may be referred to by their commonly accepted
single-letter codes.
[0077] As to amino acid sequences, one of skill will recognize that
individual substitutions, deletions or additions to a nucleic acid,
peptide, polypeptide, or protein sequence which alters, adds or
deletes a single amino acid or a small percentage of amino acids in
the encoded sequence is a "conservatively modified variant" where
the alteration results in the substitution of an amino acid with a
chemically similar amino acid (i.e., hydrophobic, hydrophilic,
positively charged, neutral, negatively charged). The chemically
similar amino acid includes, without limitation, a
naturally-occurring amino acid such as an L-amino acid, a
stereoisomer of a naturally occurring amino acid such as a D-amino
acid, and an unnatural amino acid such as an amino acid analog,
amino acid mimetic, synthetic amino acid, N-substituted glycine,
and N-methyl amino acid. Exemplified hydrophobic amino acids
include valine, leucine, isoleucine, methionine, phenylalanine, and
tryptophan. Exemplified aromatic amino acids include phenylalanine,
tyrosine and tryptophan. Exemplified aliphatic amino acids include
serine and threonine. Exemplified basic amino acids include lysine,
arginine and histidine. Exemplified amino acids with carboxylate
side-chains include aspartate and glutamate. Exemplified amino
acids with carboxamide side chains include asparagines and
glutamine. Conservative substitution tables providing functionally
similar amino acids are well known in the art. Such conservatively
modified variants are in addition to and do not exclude polymorphic
variants, interspecies homologs, and alleles of the invention.
[0078] Conservative substitution tables providing functionally
similar amino acids are well known in the art. For example,
substitutions may be made wherein an aliphatic amino acid (e.g., G,
A, I, L, or V) is substituted with another member of the group.
Similarly, an aliphatic polar-uncharged group such as C, S, T, M,
N, or Q, may be substituted with another member of the group; and
basic residues, e.g., K, R, or H, may be substituted for one
another. In some embodiments, an amino acid with an acidic side
chain, e.g., E or D, may be substituted with its uncharged
counterpart, e.g., Q or N, respectively; or vice versa. Each of the
following eight groups contains other exemplary amino acids that
are conservative substitutions for one another: [0079] 1) Alanine
(A), Glycine (G); [0080] 2) Aspartic acid (D), Glutamic acid (E);
[0081] 3) Asparagine (N), Glutamine (Q); [0082] 4) Arginine (R),
Lysine (K); [0083] 5) Isoleucine (I), Leucine (L), Methionine (M),
Valine (V); [0084] 6) Phenylalanine (F), Tyrosine (Y), Tryptophan
(W); [0085] 7) Serine (S), Threonine (T); and [0086] 8) Cysteine
(C), Methionine (M) [0087] (see, e.g., Creighton, Proteins
(1984)).
[0088] As used herein, the term "linker" refers to a moiety that
possesses one or more different reactive functional groups that
allows for covalent attachment of moieties such as a peptide to a
chelating agent. Preferably, the linking moiety possesses two
different reactive functional groups, i.e., a heterobifunctional
linker. Suitable linkers include, without limitation, those
available from Pierce Biotechnology, Inc. (Rockford, Ill.). In
preferred embodiments of the present invention, the linker provides
a carboxyl group for the attachment of a chelating agent and an
amino group for the attachment of a peptide. However, one skilled
in the art understands that any reactive functional group can be
present on the linker, as long as it is compatible with a
functional group on the moiety that is to be covalently
attached.
[0089] Linkers useful in the present invention includes those
possessing one or more different reactive functional groups that
allow for covalent attachment of moieties such as a peptide to a
chelating agent. The linking moiety possesses two or more different
reactive functional groups.
[0090] In some cases multivalent linkers can be used. Suitable
linkers include, without limitation, those available from Pierce
Biotechnology, Inc. (Rockford, Ill.). In preferred embodiments of
the present invention, the linker provides a carboxyl group for the
attachment of a chelating agent and an amino group for the
attachment of a peptide. However, one skilled in the art
understands that any reactive functional group can be present on
the linker, as long as it is compatible with a functional group on
the moiety that is to be covalently attached. As used herein, the
term "chelating agent-linker conjugate" refers to a chelating agent
covalently attached to a linker. Such chelating agent-linker
conjugates can be attached to a peptide via a functional group
present on the linker. Some suitable linkers include, but are not
limited to, .beta.-alanine, 2,2'-ethylenedioxy bis(ethylamine)
monosuccinamide (Ebes) and bis(Ebes)-Lys. Other suitable linkers
include those with biotin. Additional linkers can be found in
Bioconjugate Techniques, Greg T. Hermanson, Academic Press, 2d ed.,
2008 (incorporated by reference in its entirety herein).
[0091] As used herein, the term "salt" refers to acid or base salts
of the compounds used in the methods of the present invention.
Illustrative examples of pharmaceutically acceptable salts are
mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid,
and the like) salts, organic carboxylic acids (acetic acid,
propionic acid, glutamic acid, citric acid and the like), organic
sulfonic acids (methanesulfonic acid), salts, quaternary ammonium
(methyl iodide, ethyl iodide, and the like) salts. It is understood
that the pharmaceutically acceptable salts are non-toxic.
Additional information on suitable pharmaceutically acceptable
salts can be found in Remington's Pharmaceutical Sciences, 17th
ed., Mack Publishing Company, Easton, Pa., 1985, which is
incorporated herein by reference.
[0092] Pharmaceutically acceptable salts of the acidic compounds of
the present invention include salts formed with bases, namely
cationic salts such as alkali and alkaline earth metal salts, such
as sodium, lithium, potassium, calcium, magnesium, as well as
ammonium salts, such as ammonium, trimethyl-ammonium,
diethylammonium, and tris-(hydroxymethyl)-methyl-ammonium
salts.
[0093] As used herein, the term "hydrate" refers to a compound that
is complexed to at least one water molecule. The compounds of the
present invention can be complexed with from 1 to 10 water
molecules.
[0094] As used herein, the terms "pharmaceutically acceptable
excipient" and "pharmaceutically acceptable carrier" refer to a
substance that aids the administration of an active agent to and
absorption by a subject. "Pharmaceutically acceptable excipient"
refers to an excipient that can be included in the compositions of
the invention and that causes no significant adverse toxicological
effect on the patient. Non-limiting examples of pharmaceutically
acceptable excipients include water, NaCl, normal saline solutions,
lactated Ringer's, normal sucrose, normal glucose, binders,
fillers, disintegrants, lubricants, coatings, sweeteners, flavors
and colors, and the like. One of skill in the art will recognize
that other pharmaceutical excipients are useful in the present
invention.
[0095] As used herein, the term "osteoporosis" refers to a disease
of increased bone fragility that results from estrogen deficiency
and aging.
[0096] As used herein, the term "isomers" refers to compounds with
the same chemical formula but which are structurally
distinguishable.
[0097] As used herein, the term "tautomer," refers to one of two or
more structural isomers which exist in equilibrium and which are
readily converted from one isomeric form to another.
[0098] As used herein, the terms "patient" or "subject" refers to a
living organism suffering from or prone to a condition that can be
treated by administration of a pharmaceutical composition as
provided herein. Non-limiting examples include humans, other
mammals and other non-mammalian animals.
[0099] As used herein, the term "therapeutically effective amount"
refers to an amount of a conjugated functional agent or of a
pharmaceutical composition useful for treating or ameliorating an
identified disease or condition, or for exhibiting a detectable
therapeutic or inhibitory effect. The effect can be detected by any
assay method known in the art.
[0100] As used herein, the terms "treat", "treating" and
"treatment" refers to any indicia of success in the treatment or
amelioration of an injury, pathology or condition, including any
objective or subjective parameter such as abatement; remission;
diminishing of symptoms or making the injury, pathology or
condition more tolerable to the patient; slowing in the rate of
degeneration or decline; making the final point of degeneration
less debilitating; improving a patient's physical or mental
well-being.
[0101] As used herein, the terms "disorder" or "condition" refer to
a state of being or health status of a patient or subject capable
of being treated with the glucocorticoid receptor modulators of the
present invention.
[0102] As used herein, the terms "a," "an," or "a(n)", when used in
reference to a group of substituents or "substituent group" herein,
mean at least one. For example, where a compound is substituted
with "an" alkyl or aryl, the compound is optionally substituted
with at least one alkyl and/or at least one aryl, wherein each
alkyl and/or aryl is optionally different. In another example,
where a compound is substituted with "a" substituent group, the
compound is substituted with at least one substituent group,
wherein each substituent group is optionally different.
[0103] Description of compounds of the present invention is limited
by principles of chemical bonding known to those skilled in the
art. Accordingly, where a group may be substituted by one or more
of a number of substituents, such substitutions are selected so as
to comply with principles of chemical bonding and to give compounds
which are not inherently unstable and/or would be known to one of
ordinary skill in the art as likely to be unstable under ambient
conditions, such as aqueous, neutral, or physiological
conditions.
III. COMPOUNDS
[0104] In some embodiments, the present invention provides a
compound of Formula I:
##STR00002##
[0105] wherein Formula I each R.sup.1 and R.sup.2 is independently
selected from H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, and
C.sub.1-6 haloalkyl. R.sup.3 is selected from H, C.sub.1-6 alkyl
and C.sub.3-8 cycloalkyl. X is selected from O, S and NH. Y is
selected from O and NH. Alternatively, R.sup.1 or R.sup.2 is
combined with Y and the atoms to which they are attached to form a
5-membered heteroaryl ring. Z is a peptide having 3-20
independently selected amino acids, wherein at least one amino acid
is selected from an unnatural amino acid and a D-amino acid. L is a
linker. D is a bisphosphonate drug. Subscripts m, n and q are each
independently from 0 to 2. Also included are the salts and isomers
of the compounds of formula I.
[0106] C.sub.3-8 cycloalkyl groups useful with the present
invention include, but are not limited to, cyclopropane,
cyclobutane, cyclopentane, cyclohexane, cycloheptane, and
cyclooctane. Preferably, C.sub.3-8 cycloalkyl groups include
cyclohexane. 5-membered heteroaryl groups useful with the present
invention, include, but are not limited to imidazole, oxazole,
isoxazole, thiazole, and isothiazole.
[0107] Amino acids useful with the present invention include,
without limitation, naturally occurring amino acids; D-amino acids;
unnatural amino acids which include, without limitation, amino acid
analogs, amino acid mimetics, N-substituted glycines, N-methyl
amino acids, phenylalanine analogs, and derivatives of lysine
(Lys), ornithine (Orn) and .alpha.,.gamma.-diaminobutyric acid
(Dbu) in either the L- or D-configuration; hydrophilic amino acids,
hydrophobic amino acids; and negatively charged amino acids.
[0108] Naturally-occurring amino acids are those encoded by the
genetic code, as well as those amino acids that are later modified,
e.g., hydroxyproline, .gamma.-carboxyglutamate and O-phosphoserine.
Naturally-occurring .alpha.-amino acids include, without
limitation, alanine (Ala), cysteine (Cys), aspartic acid (Asp),
glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine
(His), isoleucine (Ile), arginine (Arg), lysine (Lys), leucine
(Leu), methionine (Met), asparagine (Asn), proline (Pro), glutamine
(Gin), serine (Ser), threonine (Thr), valine (Val), tryptophan
(Trp), tyrosine (Tyr), and combinations thereof.
[0109] Stereoisomers of a naturally-occurring .alpha.-amino acids
include, without limitation, D- and L-amino acids. D-amino acids
suitable for use in the present invention include, without
limitation, D-alanine (D-Ala), D-cysteine (D-Cys), D-aspartic acid
(D-Asp), D-glutamic acid (D-Glu), D-phenylalanine (D-Phe),
D-histidine (D-His), D-isoleucine (D-Ile), D-arginine (D-Arg),
D-lysine (D-Lys), D-leucine (D-Leu), D-methionine (D-Met),
D-asparagine (D-Asn), D-proline (D-Pro), D-glutamine (D-Gln),
D-serine (D-Ser), D-threonine (D-Thr), D-valine (D-Val),
D-tryptophan (D-Trp), D-tyrosine (D-Tyr), and combinations thereof
In some other embodiments, the D-amino acid is selected from a
D-.alpha.-amino acid, a D-.beta.-amino acid, a D-.gamma.-amino
acid, and a combination thereof. In yet another embodiment, the
D-.alpha.-amino acid is selected from a stereoisomer of a
naturally-occurring .alpha.-amino acid, an unnatural
D-.alpha.-amino acid, and a combination thereof.
[0110] Unnatural amino acids include, without limitation, amino
acid analogs, amino acid mimetics, N-substituted glycines, N-methyl
amino acids, phenylalanine analogs, and derivatives of lysine
(Lys), ornithine (Orn) and .alpha.,.gamma.-diaminobutyric acid
(Dbu) in either the L- or D-configuration that function in a manner
similar to the naturally-occurring amino acids. Unnatural amino
acids are not encoded by the genetic code, and can, but do not
necessarily, have the same basic structure or function as a
naturally occurring amino acid.
[0111] Unnatural amino acids useful with the present invention
include, but are not limited to azetidinecarboxylic acid,
2-aminoadipic acid, 3-aminoadipic acid, beta-alanine,
aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid,
6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid,
3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine,
2,4-diaminoisobutyric acid, desmosine, 2,2'-diaminopimelic acid,
2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine,
homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline,
4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine,
N-methylglycine, N-methylisoleucine, N-methylpentylglycine,
N-methylvaline, naphthalanine, norvaline, ornithine, pentylglycine,
pipecolic acid, thioproline, aminophenylalanine, hydroxytyrosine,
and aminotyrosine.
[0112] In some other embodiments, the unnatural amino acid is
selected from 1-aminocyclopentane-1-carboxylic acid (Acp),
1-aminocyclobutane-1-carboxylic acid (Acb),
1-aminocyclopropane-1-carboxylic acid (Acpc), citrulline (Cit),
homocitrulline (HoCit), .alpha.-aminohexanedioic acid (Aad),
3-(4-pyridyl)alanine (4-Pal), 3-(3-pyridyl)alanine (3-Pal),
propargylglycine (Pra), .alpha.-aminoisobutyric acid (Aib),
.alpha.-aminobutyric acid (Abu), norvaline (Nva),
.alpha.,.beta.-diaminopropionic acid (Dpr),
.alpha.,.gamma.-diaminobutyric acid (Dbu),
.alpha.-tert-butylglycine (Bug), 3,5-dinitrotyrosine Tyr(3,5-di
NO.sub.2), norleucine (Nle), 3-(2-naphthyl)alanine (Nal-2),
3-(1-naphthyl)alanine (Nal-1), cyclohexylalanine (Cha),
di-n-propylglycine (Dpg), cyclopropylalanine (Cpa), homoleucine
(Hle), homoserine (HoSer), homoarginine (Har), homocysteine (Hcy),
methionine sulfoxide (Met(O)), methionine methylsulfonium (Met
(S-Me)), .alpha.-cyclohexylglycine (Chg), 3-benzo-thienylalanine
(Bta), taurine (Tau), hydroxyproline (Hyp), O-benzyl-hydroxyproline
(Hyp(Bzl)), homoproline (HoPro), .beta.-homoproline (.beta.HoPro),
thiazolidine-4-carboxylic acid (Thz), nipecotic acid (Nip),
isonipecotic acid (IsoNip),
3-carboxymethyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (Cptd),
tetrahydro-isoquinoline-3-carboxylic acid (3-Tic), 5H-thiazolo
[3,2-a]pyridine-3-carboxylic acid (Btd), 3-aminobenzoic acid
(3-Abz), 3-(2-thienyl)alanine (2-Thi), 3-(3-thienyl)alanine
(3-Thi), .alpha.-aminooctanedioc acid (Asu), diethylglycine (Deg),
4-amino-4-carboxy-1,1-dioxo-tetrahydrothiopyran (Acdt),
1-amino-1-(4-hydroxycyclohexyl) carboxylic acid (Ahch),
1-amino-1-(4-ketocyclohexyl)carboxylic acid (Akch),
4-amino-4-carboxytetrahydropyran (Actp), 3-nitrotyrosine
(Tyr(3-NO.sub.2)), 1-amino-1-cyclohexane carboxylic acid (Ach),
1-amino-1-(3-piperidinyl)carboxylic acid (3-Apc),
1-amino-1-(4-piperidinyl)carboxylic acid (4-Apc),
2-amino-3-(4-piperidinyl) propionic acid (4-App),
2-aminoindane-2-carboxylic acid (Aic), 2-amino-2-naphthylacetic
acid (Ana), (2S,5R)-5-phenylpyrrolidine-2-carboxylic acid (Ppca),
4-thiazoylalanine (Tha), 2-aminooctanoic acid (Aoa),
2-aminoheptanoic acid (Aha), ornithine (Orn),
azetidine-2-carboxylic acid (Aca),
.alpha.-amino-3-chloro-4,5-dihydro-5-isoazoleacetic acid (Acdi),
thiazolidine-2-carboxylic acid (Thz(2-COOH)), allylglycine (Agl),
4-cyano-2-aminobutyric acid (Cab), 2-pyridylalanine (2-Pal),
2-quinoylalanine (2-Qal), cyclobutylalanine (Cba), a phenylalanine
analog, a lysine derivative, a ornithine (Orn) derivative, an
.alpha.,.gamma.-diaminobutyric acid Dbu derivative, stereoisomers
thereof, and combinations thereof (see, Liu and Lam, Anal.
Biochem., 295:9-16 (2001)). As such, the unnatural .alpha.-amino
acids are present either as unnatural L-.alpha.-amino acids,
unnatural D-.alpha.-amino acids, or combinations thereof.
[0113] In some embodiments, the unnatural amino acids is selected
from compounds of Table 1:
TABLE-US-00001 TABLE 1 Unnatural amino acids useful with the
present invention. ##STR00003## ##STR00004## ##STR00005##
##STR00006##
[0114] Suitable amino acid analogs include, without limitation,
homoserine, norleucine, methionine sulfoxide, methionine methyl
sulfonium.
[0115] Suitable amino acid mimetics include, without limitation,
.beta.-amino acids and .gamma.-amino acids. Suitable R groups for
.beta.- or .gamma.-amino acids include, but are not limited to,
side-chains present in naturally-occurring amino acids and
unnatural amino acids.
[0116] N-substituted glycines suitable for use in the present
invention include, without limitation, N-(2-aminoethyl)glycine,
N-(3-aminopropyl)glycine, N-(2-methoxyethyl)glycine,
N-benzylglycine, (S)--N-(1-phenylethyl)glycine,
N-cyclohexylmethylglycine, N-(2-phenylethyl)glycine,
N-(3-phenylpropyl)glycine, N-(6-aminogalactosyl)glycine,
N-(2-(3'-indolylethyl)glycine, N-(2-(p-methoxyphenylethyl))glycine,
N-(2-(p-chlorophenylethyl)glycine, and
N-[2-(p-hydroxyphenylethyl)]glycine. N-substituted glycine
oligomers, referred to herein as "peptoids," have been shown to be
protease resistant (Miller et al., Drug Dev. Res., 35:20-32
(1995)). As such, peptoids containing at least one unnatural
.alpha.-amino acid, D-amino acid, or a combination thereof are
within the scope of the present invention.
[0117] Suitable N-methyl amino acids include N-methyl-Ala,
N-methyl-Cys, N-methyl-Asp, N-methyl-Glu, N-methyl-Phe,
N-methyl-Gly, N-methyl-His, N-methyl-Ile, N-methyl-Arg,
N-methyl-Lys, N-methyl-Leu, N-methyl-Met, N-methyl-Asn,
N-methyl-Gln, N-methyl-Ser, N-methyl-Thr, N-methyl-Val,
N-methyl-Trp, N-methyl-Tyr, N-methyl-Acp, N-methyl-Acb,
N-methyl-Acpc, N-methyl-Cit, N-methyl-HoCit, N-methyl-Aad,
N-methyl-4-Pal, N-methyl-3-Pal, N-methyl-Pra, N-methyl-Aib,
N-methyl-Abu, N-methyl-Nva, N-methyl-Dpr, N-methyl-Dbu,
N-methyl-Nle, N-methyl-Nal-2, N-methyl-Nal-1, N-methyl-Cha,
N-methyl-Cpa, N-methyl-Hle, N-methyl-HoSer, N-methyl-Har,
N-methyl-Hcy, N-methyl-Chg, N-methyl-Bta, N-methyl-2-Thi,
N-methyl-3-Thi, N-methyl-Asu, N-methyl-Acdt, N-methyl-Ahch,
N-methyl-Akch, N-methyl-Actp, N-methyl-Tyr(3-NO.sub.2),
N-methyl-Ach, N-methyl-3-Apc, N-methyl-4-Apc, N-methyl-4-App,
N-methyl-Tha, N-methyl-Aoa, N-methyl-Aha, N-methyl-Orn,
N-methyl-Aca, N-methyl-Agl, N-methyl-Cab, N-methyl-2-Pal,
N-methyl-Cba, N-methyl-HoPhe, N-methyl-Phg,
N-methyl-Phe(4-NH.sub.2), N-methyl-4-Phe(4-Me), N-methyl-Phe(4-F),
N-methyl-Phe(4-Cl), N-methyl-Phe(2-Br), N-methyl-Phe(3-Br),
N-methyl-Phe(4-Br), N-methyl-Phe(3-CF.sub.3),
N-methyl-Phe(4-CF.sub.3), N-methyl-Phe(4-NO.sub.2),
N-methyl-Phe(4-CN), N-methyl-Bpa, N-methyl-Phg(4-Cl),
N-methyl-Phg(4-Br), N-methyl-Tyr(Me), N-methyl-Lys38,
N-methyl-Lys27, N-methyl-Lys73, N-methyl-Lys55, N-methyl-Lys28,
N-methyl-Lys72, N-methyl-Lys12, N-methyl-Lys123, N-methyl-Lys63,
N-methyl-Lys124, N-methyl-Lys82, N-methyl-Lys31, N-methyl-Lys15,
N-methyl-Lys125, N-methyl-Lys43, N-methyl-Lys24, N-methyl-Lys5,
N-methyl-Lys4, N-methyl-Lys50, N-methyl-Lys81, N-methyl-Orn38,
N-methyl-Orn27, N-methyl-Orn73, N-methyl-Orn55, N-methyl-Orn28,
N-methyl-Orn72, N-methyl-Orn12, N-methyl-Orn123, N-methyl-Orn63,
N-methyl-Orn124, N-methyl-Orn82, N-methyl-Orn31, N-methyl-Orn15,
N-methyl-Orn125, N-methyl-Orn43, N-methyl-Orn24, N-methyl-Orn5,
N-methyl-Orn4, N-methyl-Orn50, N-methyl-Orn81, N-methyl-Dbu38,
N-methyl-Dbu27, N-methyl-Dbu73, N-methyl-Dbu55, N-methyl-Dbu28,
N-methyl-Dbu72, N-methyl-Dbu12, N-methyl-Dbu123, N-methyl-Dbu63,
N-methyl-Dbu124, N-methyl-Dbu82, N-methyl-Dbu31, N-methyl-Dbu15,
N-methyl-Dbu125, N-methyl-Dbu43, N-methyl-Dbu24, N-methyl-Dbu5,
N-methyl-Dbu4, N-methyl-Dbu50, N-methyl-Dbu81, stereoisomers
thereof, and combinations thereof.
[0118] Suitable phenylalanine analogs useful with the present
invention include, without limitation, homophenylalanine (HoPhe),
phenylglycine (Phg), 3,3-diphenylalanine (Dpa),
4-aminophenylalanine (Phe(4-NH.sub.2)), 2-methylphenylalanine
(Phe(2-Me)), 3-methylphenylalanine (Phe(3-Me)),
4-methylphenylalanine (Phe(4-Me)), 4-azidophenylalanine
(Phe(4-N.sub.3)), 2-fluorophenylalanine (Phe(2-F)),
3-fluorophenylalanine (Phe(3-F)), 4-fluorophenylalanine (Phe(4-F)),
2-chlorophenylalanine (Phe(2-Cl)), 3-chlorophenylalanine
(Phe(3-Cl)), 4-chlorophenylalanine (Phe(4-Cl)),
2-bromophenylalanine (Phe(2-Br)), 3-bromophenylalanine (Phe(3-Br)),
4-bromophenylalanine (Phe(4-Br)), 2-iodophenylalanine (Phe(2-I)),
3-iodophenylalanine (Phe(3-I)), 4-iodophenylalanine (Phe(4-I)),
2-trifluoromethylphenylalanine (Phe(2-CF.sub.3)),
3-trifluoromethylphenylalanine (Phe(3-CF.sub.3)),
4-trifluoromethylphenylalanine (Phe(4-CF.sub.3)),
2-methoxyphenylalanine (Phe(2-OMe)), 3-methoxyphenylalanine
(Phe(3-OMe)), 2-nitrophenylalanine (Phe(2-NO.sub.2)),
3-nitrophenylalanine (Phe(3-NO.sub.2)), 4-nitrophenylalanine
(Phe(4-NO.sub.2)), 2-cyanophenylalanine (Phe(2-CN)),
3-cyanophenylalanine (Phe(3-CN)), 4-cyanophenylalanine (Phe(4-CN)),
3,4-dimethoxyphenylalanine (Phe(3,4-di OMe)),
3,4-difluorophenylalanine (Phe(3,4-di F)),
3,5-difluorophenylalanine (Phe(3,5-di F)),
2,4-dichlorophenylalanine (Phe(2,4-di Cl)),
3,4-dichlorophenylalanine (Phe(3,4-di Cl)), 4-benzoylphenylalanine
(Bpa), 4-carboxyphenylalanine (Phe(4-COOH)), 4,4'-biphenylalanine
(Bip), 2,3,4,5,6-pentafluorophenylalanine (Phe(F.sub.5)),
3,4,5-trifluorophenylalanine (Phe(F.sub.3)), 4-chlorophenylglycine
(Phg(4-Cl)), 2-chlorophenylglycine (Phg(2-Cl)),
3-chlorophenylglycine (Phg(3-Cl)), 4-bromophenylglycine
(Phg(4-Br)), 2-bromophenylglycine (Phg(2-Br)), 3-bromophenylglycine
(Phg(3-Br)), 4-ethylphenylalanine (Phe(4-Et)),
4-ethoxyphenylalanine (Phe(4-OEt)), 4-butoxyphenylalanine
(Phe(4-OBu)), O-methyltyrosine (Tyr(Me)), O-benzyltyrosine
(Tyr(Bz1)), 3,5-dibromotyrosine (Tyr(diBr)), 3,5-diiodotyrosine
(Tyr(diI)), homotyrosine (HoTyr), 3-chlorotyrosine (Tyr(3-Cl)),
stereoisomers thereof, and combinations thereof.
[0119] Suitable derivatives of lysine (Lys), ornithine (Orn) and
.alpha.,.gamma.-diaminobutyric acid (Dbu) useful with the present
invention include, without limitation, Lys38, Lys27, Lys73, Lys55,
Lys28, Lys72, Lys12, Lys123, Lys63, Lys124, Lys82, Lys31, Lys15,
Lys125, Lys43, Lys24, Lys5, Lys4, Lys50, Lys81, Orn38, Orn27,
Orn73, Orn55, Orn28, Orn72, Orn12, Orn123, Orn63, Orn124, Orn82,
Orn31, Orn15, Orn125, Orn43, Orn24, Orn5, Orn4, Orn50, Orn81,
Dbu38, Dbu27, Dbu73, Dbu55, Dbu28, Dbu72, Dbu12, Dbu123, Dbu63,
Dbu124, Dbu82, Dbu31, Dbu15, Dbu125, Dbu43, Dbu24, Dbu5, Dbu4,
Dbu50, Dbu81, stereoisomers thereof, and combinations thereof.
Derivatives of Orn and Dbu are similar to the lysine derivatives
with corresponding carboxylic acid attached to the side chain of
Orn and Dbu, respectively.
[0120] Suitable hydrophilic amino acids useful with the present
invention include, without limitation, Val, Leu, Ile, Met, and Phe
and stereoisomers thereof.
[0121] Suitable hydrophobic amino acids useful with the present
invention include, without limitation, the compounds of Table
2:
TABLE-US-00002 TABLE 2 Hydrophobic amino acids useful in the
present invention. No. X.sub.AA Structure 1 Ile ##STR00007## 2 Ala
##STR00008## 3 Abu ##STR00009## 4 Leu ##STR00010## 5 Pra
##STR00011## 6 Chg ##STR00012## 7 Nva ##STR00013## 8 Phg
##STR00014## 9 Cha ##STR00015## 10 Ach ##STR00016## 11 Ppca
##STR00017## 12 Ana ##STR00018## 13 Bpa ##STR00019## 14 Val
##STR00020## 15 Acpc ##STR00021## 16 Thi ##STR00022## 17 Nle
##STR00023## 18 D-Nal-2 ##STR00024## 19 Aic ##STR00025## 20 D-Phe
##STR00026## 21 HoPhe ##STR00027## 22 Tyr ##STR00028## 23 Tyr(Me)
##STR00029## 24 Phe(3-Cl) ##STR00030## 25 Tyr(diI) ##STR00031## 26
Phe(4-Me) ##STR00032##
[0122] In some other embodiments, the hydrophobic amino acid is
selected from compounds of Table 3:
TABLE-US-00003 TABLE 3 Hydrophobic amino acids useful in the
present invention. No. X.sub.AA Structure 1 Nle ##STR00033## 2 Leu
##STR00034## 3 Pra ##STR00035## 4 HLe ##STR00036## 5 Cpa
##STR00037## 6 Cha ##STR00038##
[0123] In some other embodiments, the hydrophobic amino acid is
independently selected from leucine (Leu), a leucine analog,
phenylalanine (Phe), a phenylalanine analog, proline (Pro), a
proline analog, valine (Val), isoleucine (Ile), glycine (Gly),
alanine (Ala), Met, norvaline (Nva),
1-aminocyclopropane-1-carboxylic acid (Acpc),
1-aminocyclobutane-1-carboxylic acid (Acb),
.alpha.-cyclohexylglycine (Chg), .alpha.-aminoisobutyric acid
(Aib), .alpha.-aminobutyric acid (Abu), 3-(2-thienyl)alanine
(2-Thi), 3-(3-thienyl)alanine (3-Thi), 3-(3-pyridyl)alanine
(3-Pal), 3-(2-naphthyl)alanine (Nal-2), 2-amino-2-naphthylacetic
acid (Ana), 3,5-dinitrotyrosine (Tyr(3,5-di NO.sub.2)),
diethylglycine (Deg),
4-amino-4-carboxy-1,1-dioxo-tetrahydrothiopyran (Acdt),
1-amino-1-(4-hydroxycyclohexyl) carboxylic acid (Ahch),
1-amino-1-(4-ketocyclohexyl)carboxylic acid (Akch),
4-amino-4-carboxytetrahydropyran (Actp), 3-nitrotyrosine
(Tyr(3-NO.sub.2)), 1-amino-1-cyclohexane carboxylic acid (Ach),
2-aminoindane-2-carboxylic acid (Aic),
(2S,5R)-5-phenylpyrrolidine-2-carboxylic acid (Ppca),
4-thiazoylalanine (Tha), 2-aminooctanoic acid (Aoa),
2-aminoheptanoic acid (Aha), and a stereoisomer thereof.
Preferably, the proline analog is hydroxyproline.
[0124] Suitable negatively charged amino acids useful with the
present invention include, without limitation, aspartic acid,
glutamic acid, .alpha.-aminohexanedioic acid,
.alpha.-aminooctanedioc acid, homoaspartic acid,
.gamma.-carboxy-glutamic acid, 4-carboxyphenylalanine, and a
stereoisomer thereof. In other embodiments, the negatively charged
amino acid is selected from Aad, Bec and Bmc.
[0125] Bisphosphonate drugs useful with the present invention
include any suitable bisphosphonate compound. Exemplary
bisphosphonate drugs include, but are not limited to, Etidronate
(Didronel), Clodronate (Bonefos, Loron), Tiludronate (Skelid),
Pamidronate (APD, Aredia), Neridronate, Olpadronate, Alendronate
(Fosamax), Ibandronate (Boniva), Risedronate (Actonel) and
Zoledronate (Zometa). Additional bisphosphonates are described
below in greater detail. One of skill in the art will appreciate
that other bisphosphonates are useful in the present invention.
[0126] Salts include, but are not limited, to sulfate, citrate,
acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate,
phosphate, acid phosphate, phosphonic acid, isonicotinate, lactate,
salicylate, citrate, tartrate, oleate, tannate, pantothenate,
bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate,
gluconate, glucaronate, saccharate, formate, benzoate, glutamate,
methanesulfonate, ethanesulfonate, benzenesulfonate,
p-toluenesulfonate, and pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Other salts
include, but are not limited to, salts with inorganic bases
including alkali metal salts such as sodium salts, lithium salts,
and potassium salts; alkaline earth metal salts such as calcium
salts, and magnesium salts; aluminum salts; and ammonium salts,
such as ammonium, trimethyl-ammonium, diethylammonium, and
tris-(hydroxymethyl)-methyl-ammonium salts. Other salts with
organic bases include salts with diethylamine, diethanolamine,
meglumine, and N,N'-dibenzylethylenediamine.
[0127] Linkers useful in the present invention includes those
possessing one or more different reactive functional groups that
allow for covalent attachment of moieties such as a peptides,
monomers, and polymers. The linking moiety possesses two or more
different reactive functional groups. In some cases multivalent
linkers can be used and multiple peptides of the present invention
and/or multiple active agents can be linked via the linker.
Suitable linkers include, without limitation, those available from
Pierce Biotechnology, Inc. (Rockford, Ill.). One skilled in the art
understands that any reactive functional group can be present on
the linker, as long as it is compatible with a functional group on
the moiety that is to be covalently attached. Some suitable linkers
include, but are not limited to, .beta.-alanine, 2,2'-ethylenedioxy
bis(ethylamine) monosuccinamide (Ebes), bis(Ebes)-Lys, and
polyethylene glycol. Other suitable linkers include those with
biotin. Additional linkers can be found in Bioconjugate Techniques,
Greg T. Hermanson, Academic Press, 2d ed., 2008 (incorporated by
reference in its entirety herein).
[0128] A person of ordinary skill in the art will recognize that
other linkers are possible with the compounds of the present
invention. Many such linkers can be found in, or prepared by the
techniques recited in, "Bioconjugate Techniques" by Greg T
Hermanson, Academic Press, San Diego, 1996, which is hereby
incorporated by reference. Furthermore, a person of ordinary skill
in the art will recognize that other linkers can be prepared based
on Click Chemistry synthetic techniques as described in Kolb, H.
C., Finn, M. G., Sharpless, K. B., Angew. Chem. Int'l. Ed. 40 (11):
2004-2021 (2001), which is hereby incorporated by reference.
Linkers useful with the present invention include those based on
the EBES and PEG moiety. The linker can include either 0 to 6 EBES
or PEG groups. EBES and PEG groups can be conjugated by the
techniques referenced above.
[0129] Acid addition salts, such as mineral acids, organic
carboxylic and organic sulfonic acids, e.g., hydrochloric acid,
methanesulfonic acid, maleic acid, are also possible provided a
basic group, such as pyridyl, constitutes part of the
structure.
[0130] The neutral forms of the compounds can be regenerated by
contacting the salt with a base or acid and isolating the parent
compound in the conventional manner. The parent form of the
compound differs from the various salt forms in certain physical
properties, such as solubility in polar solvents, but otherwise the
salts are equivalent to the parent form of the compound for the
purposes of the present invention.
[0131] In some embodiments, the portion of the compound bonded to Z
of Formula I has a formula selected from:
##STR00039##
[0132] In some other embodiments, the portion of the compound of
Formula I bonded to Z has a formula selected from:
##STR00040##
[0133] In some embodiments, the portion of the compound of Formula
I bonded to Z has a formula selected from:
##STR00041##
[0134] In some other embodiments, the portion of the compound of
Formula I bonded to Z has a formula selected from:
##STR00042##
[0135] In some embodiments, the portion of the compound of Formula
I bonded to Z has a formula selected from:
##STR00043##
[0136] In some other embodiments, the portion of the compound of
Formula I bonded to Z has the formula:
##STR00044##
[0137] In some embodiments, peptide Z has the following
structure:
--X.sub.1--X.sub.2--X.sub.3--X.sub.4--Y.sub.1--,
wherein X.sub.1 can be a hydrophobic amino acid or derivatives of
lysine, ornithine (Orn) and .alpha.,.gamma.-diaminobutyric acid
(Dbu); X.sub.2 can be a negatively charged amino acid; X.sub.3 can
be a hydrophobic amino acid; X.sub.4 can be a naturally-occurring
amino acid, an unnatural amino acid, or a D-amino acid; Y.sub.1 can
be a peptide fragment having m independently selected amino acids;
and m is an integer of from 0 to 20. In another embodiment, m is an
integer of from 0 to 15, preferably of from 0 to 10, more
preferably of from 0 to 5, and still more preferably of from 0 to
3. In another embodiment, Y.sub.1 has a carboxyl-terminal group
selected from the group consisting of an amide group and a
carboxylic acid group.
[0138] In some other embodiments, peptide Z has the following
structure:
--X.sub.1--X.sub.2--X.sub.3--Y.sub.1--,
wherein X.sub.1, X.sub.2, X.sub.3 and Y.sub.1 are as defined
above.
[0139] In other embodiments, peptide Z of Formula I has the
formula:
--X.sub.AA1--X.sub.AA2--X.sub.AA3--(X.sub.AA4).sub.p--.
X.sub.AA1 is selected from a hydrophobic amino acid and derivatives
of lysine, homolysine (Hly), ornithine (Orn) and
.alpha.,.gamma.-diaminobutyric acid (Dbu). X.sub.AA2 is a
negatively charged amino acid. X.sub.AA3 is a hydrophobic amino
acid. X.sub.AA4 is selected from a naturally-occurring amino acid,
an unnatural amino acid, and a D-amino acid. Subscript p is 0 or 1.
Suitable hydrophobic amino acids, derivatives of lysine, homolysine
(Hly), ornithine (Orn) and .alpha.,.gamma.-diaminobutyric acid
(Dbu), negatively charged amino acids, naturally-occurring amino
acids, unnatural amino acids, and D-amino acids useful with the
present invention are described above.
[0140] In other embodiments, X.sub.AA1 can be Leu, a leucine
analog, Lys38, or a stereoisomer thereof. In another embodiment,
X.sub.AA2 can be Asp, Glu, Aad, or a stereoisomer thereof. In a
preferred embodiment, X.sub.AA2 is Aad. In yet another embodiment,
X.sub.AA3 can be Leu, a Leu analog, Phe, a Phe analog, Val, Ile,
Ala, Nva, Acpc, Chg, Aib, Abu, Aic, NaI-2, Ana, or a stereoisomer
thereof. In still yet another embodiment, X.sub.AA4 can be a
hydrophobic amino acid, a negatively charged amino acid, or a
stereoisomer thereof. Preferably, the hydrophobic amino acid can be
Pro, a Pro analog, or a stereoisomer thereof. Preferably, the Pro
analog is Hyp.
[0141] In another embodiment, peptide Z can be -Nle-Aad-Chg-D-Tyr,
-Leu-Aad-Chg-D-Gln-D-Tyr, -Cpa-Asp-Phg-D-Glu-D-Ser,
-Leu-Aad-Val-Hyp (SEQ ID NO:1), -Nle-Aad-Val-D-Thr-Hyp-D-Asn,
-Cha-Aad-Nle-D-Gln-D-Asn, -Cpa-Glu-Val-D-Asp-D-Ala,
-Hle-Aad-Phe-Chg (SEQ ID NO:2), -Nle-Asp-Pra-Gly-Hyp (SEQ ID NO:3),
-Lys38-Aad-Leu-D-Pro, -Cha-Asp-Val-D-Glu-D-Gln, -Cpa-Aad-Ile-D-Asp,
-Hle-Aad-Aib-D-3-Pal, -Lys38-Glu-Acpc-Nle-D-Asp-D-Gln,
-Nle-Asp-Val-Ach-D-Ala, -Leu-Aad-Ala-Hyp, -Cpa-Asp-Nva-D-Glu,
-Leu-Aad-Nva-Hyp-D-Glu, -Hle-Asp-Ile-D-Asp-HoSer-D-Asn,
-Cpa-Aad-Aib-D-Thi, -Cpa-Aad-Acpc-Hyp (SEQ ID NO:4),
-Cpa-Aad-Val-D-Tyr-D-Asp, -Nle-Asp-Ala-Aad-Aic (SEQ ID NO:5),
-Cha-Asp-HoPhe-Hyp-D-3-Pal-Nle-Ach, -Nle-Aad-Chg-Hyp-Aad (SEQ ID
NO:6), -Nle-Aad-Chg-Hyp-D-Val-D-Asp-D-Asp,
-Cpa-Aad-Chg-Pro-Aad-Phe(3-Cl)-Aad (SEQ ID NO:7),
-Cpa-Aad-Chg-Acp-D-Asp-D-Glu, -Nle-Aad-Chg-Hyp-D-Glu-Ach,
-Hle-Aad-Val-Hyp-Chg (SEQ ID NO:8), -Nle-Glu-Phg-Acp-Aad (SEQ ID
NO:9), -Nle-Aad-Val-D-Glu, -Lys38-Aad-Acpc-D-Asp,
-Lys38-Aad-Acpc-D-Asn-D-Asn, -Lys38-Aad-D-Phe-D-3-Pal,
-Nle-Aad-Cha-D-Glu, -Hle-Aad-Ile-D-Asp-Nle,
-Lys38-Aad-Aic-D-Glu-D-Tyr, -Cpa-Aad-Nle-D-Pro, -Lys-Aad-Chg-D-Glu,
-Cpa-Aad-Chg-D-Ser-Gly, -Cpa-Aad-Nle-Aad (SEQ ID NO:10),
-Cpa-Aad-Acpc-Aad (SEQ ID NO:11), -Leu-Aad-Acpc-Aad (SEQ ID NO:12),
-Nle-Aad-Nle-Chg-D-Glu, -HoPhe-Aad-D-Nal-2-D-Glu,
-Lys38-Aad-D-Phe-4-Pal-D-Asn, -Lys38-Aad-D-Phe-D-Asp,
-Lys38-Aad-D-Phe-D-Ser-Nva, or -Lys38-Aad-D-Phe-D-Val.
[0142] In some other embodiments, peptide Z can be
-HoPhe-Asp-Phg-Pro-Gly-D-Tyr-Aad, -Hle-Asp-Ile-Pro-Chg (SEQ ID
NO:13), -Cpa-Asp-Ile-Hyp-D-Thr-D-Asn-Nva,
-Cha-Asp-Pra-Pro-D-Pro-Gly-D-Ser, -Cha-Asp-Leu-Hyp-HoCit-HoCit (SEQ
ID NO:14), -Lys12-Aad-Nva-Hyp-Hyp (SEQ ID NO:15),
-Hle-Asp-Val-Pro-D-3-Pal-Nva-Ana, -Cpa-Asp-Abu-Acp-Nva-D-Asp,
-Cha-Asp-Tyr-Pro-D-His, -Leu-Aad-Abu-Ppca-Ach-D-Tyr,
-Leu-Asp-Nva-Hyp-Gly-D-Phe-Nva,
-Nle-Asp-Ile-Pro-Aib-D-HoPhe-Tyr(Me),
-Cpa-Glu-Tyr-Pro-Chg-Aad-D-Glu, -Hle-Asp-Nva-Pro-D-Glu,
-Nle-Asp-Ile-Hyp-Hyp (SEQ ID NO:16), -Ile-Aad-Ile-Ppca-D-Ile,
-HoPhe-Asp-Ala-Pro-Aib-D-Ala, -Hle-Glu-Abu-Hyp-HoCit-HoCit (SEQ ID
NO:17), -Leu-Asp-Leu-Ppca-HoCit-D-Thr-D-Pro,
-HoPhe-Asp-Nva-Ppca-D-Ala, -Nle-Asp-Val-Pro-HoCit-Gly (SEQ ID
NO:18), -Cpa-Aad-Abu-Pro-D-Ala-D-Tyr-D-Phe(4-Me),
-Nle-Glu-Ala-D-Thi, -Cha-Asp-Nle-D-Gln, -Hle-Aad-Ile-D-Asp-D-Phe,
-Leu-Asp-D-Phe-Aic, -Cpa-Asp-Leu-D-Thi, -HoPhe-Asp-Abu-D-Asn,
-Cha-Aad-Val-Ana-Ahch (SEQ ID NO:19), -Hle-Asp-Acpc-D-Ala,
-Leu-Aad-Ana-D-Pro, -Lys38-Asp-Phe(3-C1)-D-Pro, -Lys
12-Asp-Nle-Hyp-D-Glu, -Lys38-Aad-D-Nal-2-D-Thr-D-Bpa,
-Cpa-Asp-Ala-D-Thi, or -HoPhe-Asp-Ala-Hyp (SEQ ID NO:20).
[0143] In some embodiments, X.sub.AA1 of peptide Z of Formula I is
lysine-A38 (Lys38), X.sub.AA2 of peptide Z of Formula I is
.alpha.-aminohexanedioic acid (Aad), X.sub.AA3 of peptide Z of
Formula I is a D-amino acid, and subscript p is 0. In some other
embodiments, peptide Z of Formula I is selected from
-Lys38-Aad-D-Phe, -Lys38-Aad-Ach, -Ly s38-Aad-D -Nal-2,
-Lys38-Aad-Ile, -Lys38-Aad-Val, and -Lys38-Aad-Leu. In other
embodiments, the present invention provides compounds of Formula I,
wherein peptide Z is -Lys38-Aad-Ach.
[0144] In some embodiments, the linker L of Formula I includes at
least one of N-(8-amino-3,6-dioxa-octyl)succinamic acid (EBES) and
polyethylene glycol (PEG).
[0145] In some other embodiments, the linker L of Formula I is
selected from:
##STR00045## ##STR00046## ##STR00047##
wherein k is from 0 to 6.
[0146] In some embodiments, the portion of the compound of Formula
I bonded to D of Formula I has the formula:
##STR00048##
R.sup.4 is selected from H, OH and halogen, R.sup.5 is selected
from H and C.sub.1-6 alkyl, and subscript t is from 1 to 6.
[0147] In some other embodiments, the portion of the compound of
Formula I bonded to D has the formula selected from:
##STR00049##
[0148] In some embodiments, the compounds of Formula I are selected
from:
##STR00050## ##STR00051## ##STR00052##
[0149] In some embodiments, the salts, hydrates, solvates, prodrug
forms, isomers, and metabolites of compounds of Formula I are
provided.
[0150] Certain compounds of the present invention can exist in
unsolvated forms as well as solvated forms, including hydrated
forms. In general, the solvated forms are equivalent to unsolvated
forms and are encompassed within the scope of the present
invention. Certain compounds of the present invention may exist in
multiple crystalline or amorphous forms. In general, all physical
forms are equivalent for the uses contemplated by the present
invention and are intended to be within the scope of the present
invention.
[0151] Certain compounds of the present invention possess
asymmetric carbon atoms (optical centers) or double bonds; the
enantiomers, racemates, diastereomers, tautomers, geometric
isomers, stereoisometric forms that may be defined, in terms of
absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)-for
amino acids, and individual isomers are encompassed within the
scope of the present invention. The compounds of the present
invention do not include those which are known in art to be too
unstable to synthesize and/or isolate. The present invention is
meant to include compounds in racemic and optically pure forms.
Optically active (R)- and (S)-, or (D)- and (L)-isomers may be
prepared using chiral synthons or chiral reagents, or resolved
using conventional techniques.
[0152] The present invention also provides compounds which are in a
prodrug form. Prodrugs of the compounds described herein are those
compounds that readily undergo chemical changes under physiological
conditions to provide the compounds of the present invention.
Additionally, prodrugs can be converted to the compounds of the
present invention by chemical or biochemical methods in an ex vivo
environment. For example, prodrugs can be slowly converted to the
compounds of the present invention when placed in a transdermal
patch reservoir with a suitable enzyme or chemical reagent.
[0153] The compounds of the invention can be synthesized by a
variety of methods known to one of skill in the art (see
Comprehensive Organic Transformations by Richard C. Larock, 1989)
or by an appropriate combination of generally well known synthetic
methods. Techniques useful in synthesizing the compounds of the
invention are both readily apparent and accessible to those of
skill in the relevant art. The discussion below is offered to
illustrate certain of the diverse methods available for use in
assembling the compounds of the invention. However, the discussion
is not intended to define the scope of reactions or reaction
sequences that are useful in preparing the compounds of the present
invention. One of skill in the art will appreciate that other
methods of making the compounds are useful in the present
invention.
[0154] One-bead one-compound (OBOC) combinatorial library methods
were used to identify bisaryl urea peptidomimetics, such as LLP2A,
as highly potent and selective ligands for the activated form of
.alpha..sub.4.beta..sub.1 integrin (Peng, L., et al., Nat Chem
Biol, 2006, 2(7): p. 381-9). Additionally, LLP2A, when
appropriately radioconjugated (DOTA/.sup.64Cu or .sup.90Y), was
shown to exhibit potential as a diagnostic or therapeutic agent
(DeNardo et al., J Nucl Med, 2009, 50: p 625-34).
[0155] The "one-bead one-compound" (OBOC) combinatorial library
method was first reported in 1991 (Lam et al., Nature, 1991, 354:p.
82-4). In essence, when a "split-mix" synthesis method (Lam et al.,
id; Houghten et al., Nature, 1991, 354:p. 84-6; Furka et al., Int.
J. Peptide Protein Res., 1991, 37:p. 487-93) is used to generate a
combinatorial library, each bead expresses only one chemical entity
(Lam et al., id; Lam et al., Chem. Rev., 1997, 97:p. 411-48).
Random libraries of millions of beads can then be screened in
parallel for a specific acceptor molecule (e.g., receptor,
antibody, enzyme, virus, whole cell, etc.). Positive beads are
physically isolated for structural determination by microsequencing
using automatic Edman degradation (Lam et al., Nature, 1991, 354:p.
82-4).
[0156] The one-bead-one compound (OBOC) combinatorial library
method synthesizes millions of compounds such that each bead
displays only one compound. Through the OBOC combinatorial library
methods, LLP2A was identified as a ligand that specifically binds
to the integrin .alpha..sub.4.beta..sub.1 (IC.sub.50=2 pM). LLP2A,
when conjugated a to near-infrared fluorescent dye, can be used to
image .alpha..sub.4.beta..sub.1-expressing cells with high
sensitivity and specificity and to guide a therapeutic compound to
the .alpha..sub.4.beta..sub.1-expressing lymphomas (Peng, L., et
al., Nat Chem Biol, 2006, 2(7): p. 381-9). The ligand is known to
direct compounds to the .alpha..sub.4.beta..sub.1-expressing
lymphomas (Peng, L., et al., Nat Chem Biol, 2006, 2(7): p. 381-9;
Peng, L., et al., Mol Cancer Ther, 2008, 7(2):p. 432-7 Aina, O. H.,
et al., Mol Pharm, 2007. 4(5): p. 631-51; Aina, O. H., et al., Mol
Cancer Ther, 2005. 4(5): p. 806-13.).
[0157] The compounds described herein can be used in combination
with one another, with other active agents known to be useful in
treating osteoporosis or promoting bone growth, or with adjunctive
agents that may not be effective alone, but may contribute to the
efficacy of the active agent. In some embodiments,
co-administration of the compounds herein with other agents
includes administering one active agent within 0.5, 1, 2, 4, 6, 8,
10, 12, 16, 20, or 24 hours of a second active agent.
Co-administration includes administering two active agents
simultaneously, approximately simultaneously (e.g., within about 1,
5, 10, 15, 20, or 30 minutes of each other), or sequentially in any
order. In some embodiments, co-administration can be accomplished
by co-formulation, i.e., preparing a single pharmaceutical
composition including both active agents. In other embodiments, the
active agents can be formulated separately. In another embodiment,
the active and/or adjunctive agents may be linked or conjugated to
one another.
[0158] Exemplary compounds of the present invention are shown in
FIG. 12.
IV. PHARMACEUTICAL COMPOSITIONS
[0159] In another embodiment, the present invention provides a
pharmaceutical composition, including a compound of the present
invention and a pharmaceutically acceptable excipient.
[0160] The compounds of the present invention can be prepared and
administered in a wide variety of oral, parenteral and topical
dosage forms. Oral preparations include tablets, pills, powder,
dragees, capsules, liquids, lozenges, cachets, gels, syrups,
slurries, suspensions, etc., suitable for ingestion by the patient.
The compounds of the present invention can also be administered by
injection, that is, intravenously, intramuscularly,
intracutaneously, subcutaneously, intraduodenally, or
intraperitoneally. Also, the compounds described herein can be
administered by inhalation, for example, intranasally.
Additionally, the compounds of the present invention can be
administered transdermally. The compounds of the present invention
can also be administered by intraocular, intravaginal, and
intrarectal routes including suppositories, insufflation, powders
and aerosol formulations (for examples of steroid inhalants, see
Rohatagi, J. Clin. Pharmacol. 35:1187-1193, 1995; Tjwa, Ann.
Allergy Asthma Immunol. 75:107-111, 1995). Accordingly, the present
invention also provides pharmaceutical compositions including a
pharmaceutically acceptable carrier or excipient and either a
compound of the present invention, or a pharmaceutically acceptable
salt of a compound of the present invention.
[0161] For preparing pharmaceutical compositions from the compounds
of the present invention, pharmaceutically acceptable carriers can
be either solid or liquid. Solid form preparations include powders,
tablets, pills, capsules, cachets, suppositories, and dispersible
granules. A solid carrier can be one or more substances, which may
also act as diluents, flavoring agents, binders, preservatives,
tablet disintegrating agents, or an encapsulating material. Details
on techniques for formulation and administration are well described
in the scientific and patent literature, see, e.g., the latest
edition of Remington's Pharmaceutical Sciences, Maack Publishing
Co, Easton Pa. ("Remington's").
[0162] In powders, the carrier is a finely divided solid, which is
in a mixture with the finely divided active component. In tablets,
the active component is mixed with the carrier having the necessary
binding properties in suitable proportions and compacted in the
shape and size desired. The powders and tablets preferably contain
from 5% or 10% to 70% of the active compound.
[0163] The compositions typically include a conventional
pharmaceutical carrier or excipient and may additionally include
other medicinal agents, carriers, adjuvants, diluents, tissue
permeation enhancers, solubilizers, and the like. Preferably, the
composition will contain about 0.01% to about 90%, preferably about
0.1% to about 75%, more preferably about 0.1% to 50%, still more
preferably about 0.1% to 10% by weight of a ligand of the present
invention or a combination thereof, with the remainder consisting
of suitable pharmaceutical carrier and/or excipients. Appropriate
excipients can be tailored to the particular composition and route
of administration by methods well known in the art, e.g.,
REMINGTON'S PHARMACEUTICAL SCIENCES, supra.
[0164] Suitable solid excipients include, but are not limited to,
magnesium carbonate; magnesium stearate; calcium phosphate; calcium
silicate; talc; pectin; dextran, dextrin, and cyclodextrin
inclusion complexes; a low melting wax; cocoa butter;
carbohydrates; sugars including, but not limited to, lactose,
dextrose, sucrose, mannitol, or sorbitol; starches including, but
not limited to, starch from corn, wheat, rice, potato, or other
plants; cellulose such as methyl cellulose,
hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose;
and gums including arabic, tragacanth, and acacia; as well as
proteins including, but not limited to, gelatin, collagen;
microcrystalline cellulose, water, saline, syrup, ethylcellulose,
and polyacrylic acids such as Carbopols, e.g., Carbopol 941,
Carbopol 980, Carbopol 981, etc.; lubricating agents; mineral oil;
wetting agents; emulsifying agents; suspending agents; preserving
agents such as methyl-, ethyl-, and propyl-hydroxy-benzoates (i.e.,
the parabens); pH adjusting agents such as inorganic and organic
acids and bases; sweetening agents; and flavoring agents;
biodegradable polymer beads. If desired, disintegrating or
solubilizing agents may be added, such as the cross-linked
polyvinyl pyrrolidone, agar, alginic acid, alginates, or a salt
thereof, such as sodium alginate.
[0165] A pharmaceutically acceptable carrier may include
physiologically acceptable compounds that act, for example, to
stabilize the compounds of the present invention or modulate their
absorption, or other excipients as desired. Physiologically
acceptable compounds include, for example, carbohydrates, such as
glucose, sucrose or dextrans, antioxidants, such as ascorbic acid
or glutathione, chelating agents, low molecular weight proteins or
other stabilizers or excipients. One skilled in the art would know
that the choice of a pharmaceutically acceptable carrier, including
a physiologically acceptable compound, depends, for example, on the
route of administration of the compounds of the present invention
and on the particular physio-chemical characteristics of the
compounds of the present invention.
[0166] Generally, such carriers should be nontoxic to recipients at
the dosages and concentrations employed. Ordinarily, the
preparation of such compositions entails combining the therapeutic
agent with buffers, antioxidants such as ascorbic acid, low
molecular weight (less than about 10 residues) polypeptides,
proteins, amino acids, carbohydrates including glucose, maltose,
sucrose or dextrins, chelating agents such as EDTA, glutathione and
other stabilizers and excipients. Neutral buffered saline or saline
mixed with nonspecific serum albumin are exemplary appropriate
diluents.
[0167] Dragee cores are provided with suitable coatings such as
concentrated sugar solutions, which may also contain gum arabic,
talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol,
and/or titanium dioxide, lacquer solutions, and suitable organic
solvents or solvent mixtures. Dyestuffs or pigments may be added to
the tablets or dragee coatings for product identification or to
characterize the quantity of active compound (i.e., dosage).
Pharmaceutical preparations of the invention can also be used
orally using, for example, push-fit capsules made of gelatin, as
well as soft, sealed capsules made of gelatin and a coating such as
glycerol or sorbitol. Push-fit capsules can contain compounds of
the present invention mixed with a filler or binders such as
lactose or starches, lubricants such as talc or magnesium stearate,
and, optionally, stabilizers. In soft capsules, the compounds of
the present invention may be dissolved or suspended in suitable
liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycol with or without stabilizers.
[0168] For preparing suppositories, a low melting wax, such as a
mixture of fatty acid glycerides or cocoa butter, is first melted
and the active component is dispersed homogeneously therein, as by
stirring. The molten homogeneous mixture is then poured into
convenient sized molds, allowed to cool, and thereby to
solidify.
[0169] Liquid form preparations include solutions, suspensions, and
emulsions, for example, water or water/propylene glycol solutions.
For parenteral injection, liquid preparations can be formulated in
solution in aqueous polyethylene glycol solution.
[0170] Aqueous solutions suitable for oral use can be prepared by
dissolving the active component in water and adding suitable
colorants, flavors, stabilizers, and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing
the finely divided active component in water with viscous material,
such as natural or synthetic gums, resins, methylcellulose, sodium
carboxymethylcellulose, hydroxypropylmethylcellulose, sodium
alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and
dispersing or wetting agents such as a naturally occurring
phosphatide (e.g., lecithin), a condensation product of an alkylene
oxide with a fatty acid (e.g., polyoxyethylene stearate), a
condensation product of ethylene oxide with a long chain aliphatic
alcohol (e.g., heptadecaethylene oxycetanol), a condensation
product of ethylene oxide with a partial ester derived from a fatty
acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or
a condensation product of ethylene oxide with a partial ester
derived from fatty acid and a hexitol anhydride (e.g.,
polyoxyethylene sorbitan mono-oleate). The aqueous suspension can
also contain one or more preservatives such as ethyl or n-propyl
p-hydroxybenzoate, one or more coloring agents, one or more
flavoring agents and one or more sweetening agents, such as
sucrose, aspartame or saccharin. Formulations can be adjusted for
osmolarity.
[0171] Also included are solid form preparations, which are
intended to be converted, shortly before use, to liquid form
preparations for oral administration. Such liquid forms include
solutions, suspensions, and emulsions. These preparations may
contain, in addition to the active component, colorants, flavors,
stabilizers, buffers, artificial and natural sweeteners,
dispersants, thickeners, solubilizing agents, and the like.
[0172] Oil suspensions can be formulated by suspending a compound
of the present invention in a vegetable oil, such as arachis oil,
olive oil, sesame oil or coconut oil, or in a mineral oil such as
liquid paraffin; or a mixture of these. The oil suspensions can
contain a thickening agent, such as beeswax, hard paraffin or cetyl
alcohol. Sweetening agents can be added to provide a palatable oral
preparation, such as glycerol, sorbitol or sucrose. These
formulations can be preserved by the addition of an antioxidant
such as ascorbic acid. As an example of an injectable oil vehicle,
see Minto, J. Pharmacol. Exp. Ther. 281:93-102, 1997. The
pharmaceutical formulations of the invention can also be in the
form of oil-in-water emulsions. The oily phase can be a vegetable
oil or a mineral oil, described above, or a mixture of these.
Suitable emulsifying agents include naturally-occurring gums, such
as gum acacia and gum tragacanth, naturally occurring phosphatides,
such as soybean lecithin, esters or partial esters derived from
fatty acids and hexitol anhydrides, such as sorbitan mono-oleate,
and condensation products of these partial esters with ethylene
oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion
can also contain sweetening agents and flavoring agents, as in the
formulation of syrups and elixirs. Such formulations can also
contain a demulcent, a preservative, or a coloring agent.
V. ADMINISTRATION
[0173] Administration of the ligands of the present invention with
a suitable pharmaceutical excipient as necessary can be carried out
via any of the accepted modes of administration. Thus,
administration can be, for example, intravenous, topical,
subcutaneous, transcutaneous, transdermal, intramuscular, oral,
intra joint, parenteral, intra-arteriole, intradermal,
intraventricular, intracranial, intraperitoneal, intralesional,
intranasal, rectal, vaginal, or by inhalation. Administration may
also be directly to the bone surface and/or into tissues
surrounding the bone.
[0174] The compositions containing a ligand or a combination of
ligands of the present invention may be administered repeatedly,
e.g., at least 2, 3, 4, 5, 6, 7, 8, or more times, or the
composition may be administered by continuous infusion. Suitable
sites of administration include, but are not limited to, skin,
bronchial, gastrointestinal, anal, vaginal, eye, and ear. The
formulations may take the form of solid, semi-solid, lyophilized
powder, or liquid dosage forms, such as, for example, tablets,
pills, capsules, powders, solutions, suspensions, emulsions,
suppositories, retention enemas, creams, ointments, lotions, gels,
aerosols, or the like, preferably in unit dosage forms suitable for
simple administration of precise dosages.
[0175] The pharmaceutical preparations are typically delivered to a
mammal, including humans and non-human mammals. Non-human mammals
treated using the present methods include domesticated animals
(i.e., canine, feline, murine, rodentia, and lagomorpha) and
agricultural animals (bovine, equine, ovine, porcine).
[0176] The pharmaceutical preparation is preferably in unit dosage
form. The term "unit dosage form" refers to physically discrete
units suitable as unitary dosages for human subjects and other
mammals (e.g., dogs), each unit containing a predetermined quantity
of active material calculated to produce the desired onset,
tolerability, and/or therapeutic effects, in association with a
suitable pharmaceutical excipient (e.g., an ampoule). In addition,
more concentrated compositions may be prepared, from which the more
dilute unit dosage compositions may then be produced. The more
concentrated compositions thus will contain substantially more
than, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times
the amount of a ligand or a combination of ligands. In such form
the preparation is subdivided into unit doses containing
appropriate quantities of the active component. The unit dosage
form can be a packaged preparation, the package containing discrete
quantities of preparation, such as packeted tablets, capsules, and
powders in vials or ampoules. Also, the unit dosage form can be a
capsule, tablet, cachet, or lozenge itself, or it can be the
appropriate number of any of these in packaged form. The
composition can, if desired, also contain other compatible
therapeutic agents. Preferred pharmaceutical preparations can
deliver the compounds of the invention in a sustained release
formulation.
[0177] Methods for preparing such dosage forms are known to those
skilled in the art (see, for example, REMINGTON'S PHARMACEUTICAL
SCIENCES, 18TH ED., Mack Publishing Co., Easton, Pa. (1990)). The
composition to be administered contains a quantity of the ligand or
combination of ligands in a pharmaceutically effective amount for
relief of a condition being treated (e.g. osteoporosis) when
administered in accordance with the teachings of this invention. In
addition, pharmaceutically acceptable salts of the ligands of the
present invention (e.g., acid addition salts) may be prepared and
included in the compositions using standard procedures known to
those skilled in the art of synthetic organic chemistry and
described, e.g., by J. March, Advanced Organic Chemistry:
Reactions, Mechanisms and Structure, 4.sup.th Ed. (New York:
Wiley-Interscience, 1992).
[0178] For oral administration, the compositions can be in the form
of tablets, capsules, emulsions, suspensions, solutions, syrups,
sprays, lozenges, powders, and sustained-release formulations.
Suitable excipients for oral administration include pharmaceutical
grades of mannitol, lactose, starch, magnesium stearate, sodium
saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium
carbonate, and the like.
[0179] In some embodiments, the pharmaceutical compositions take
the form of a pill, tablet, or capsule, and thus, the composition
can contain, along with the ligands or combination of ligands, any
of the following: a diluent such as lactose, sucrose, dicalcium
phosphate, and the like; a disintegrant such as starch or
derivatives thereof; a lubricant such as magnesium stearate and the
like; and a binder such a starch, gum acacia, polyvinylpyrrolidone,
gelatin, cellulose and derivatives thereof. The ligands can also be
formulated into a suppository disposed, for example, in a
polyethylene glycol (PEG) carrier.
[0180] Liquid compositions can be prepared by dissolving or
dispersing a ligand or a combination of ligands and optionally one
or more pharmaceutically acceptable adjuvants in a carrier such as,
for example, aqueous saline (e.g., 0.9% w/v sodium chloride),
aqueous dextrose, glycerol, ethanol, and the like, to form a
solution or suspension, e.g., for oral, topical, or intravenous
administration. The ligands of the present invention can also be
formulated into a retention enema.
[0181] For topical administration, the compositions of the present
invention can be in the form of emulsions, lotions, gels, creams,
jellies, solutions, suspensions, ointments, and transdermal
patches. For delivery by inhalation, the composition can be
delivered as a dry powder or in liquid form via a nebulizer. For
parenteral administration, the compositions can be in the form of
sterile injectable solutions and sterile packaged powders.
Preferably, injectable solutions are formulated at a pH of about
4.5 to about 7.5.
[0182] The compositions of the present invention can also be
provided in a lyophilized form. Such compositions may include a
buffer, e.g., bicarbonate, for reconstitution prior to
administration, or the buffer may be included in the lyophilized
composition for reconstitution with, e.g., water. The lyophilized
composition may further comprise a suitable vasoconstrictor, e.g.,
epinephrine. The lyophilized composition can be provided in a
syringe, optionally packaged in combination with the buffer for
reconstitution, such that the reconstituted composition can be
immediately administered to a patient.
[0183] Generally, administered dosages will be effective to deliver
picomolar to micromolar concentrations of the ligand to the
appropriate site or sites. However, one of ordinary skill in the
art understands that the dose administered will vary depending on a
number of factors, including, but not limited to, the particular
ligand or set of ligands to be administered, the mode of
administration, the type of application (e.g., imaging,
therapeutic), the age of the patient, and the physical condition of
the patient. Preferably, the smallest dose and concentration
required to produce the desired result should be used. Dosage
should be appropriately adjusted for children, the elderly,
debilitated patients, and patients with cardiac and/or liver
disease. Further guidance can be obtained from studies known in the
art using experimental animal models for evaluating dosage.
However, the increased cell binding affinity and specificity
associated with the ligands of the present invention permits a
wider margin of safety for dosage concentrations and for repeated
dosing.
[0184] Individuals to be treated using methods of the present
invention can be any mammal. For example, local increase in bone
can be used for fracture healing, fusion (arthrodesis), orthopedic
reconstruction, and periodontal repair. Systemic increase in bone
would be for treatment of low bone mass, i.e. osteoporosis. Such
individuals include a dog, cat, horse, cow, or goat, particularly a
commercially important animal or a domesticated animal, more
particularly a human.
[0185] In other embodiments, the present invention provides a
method of promoting systemic bone growth. Systemic bone growth
refers to the growth of bone throughout the subject, and can effect
all the bones in the subject's body. A subject in need of systemic
bone growth can suffer from a variety of ailments and disease
states. In some embodiments, the subject suffers from a low bone
mass phenotype disease. Low bone mass can be determined by a
variety of methods known to one of skill in the art. For example,
low bone mass can be characterized by a T-score less than about -1.
Low bone mass phenotype diseases can include osteoporosis,
osteopenia, and osteoporosis-pseudoglioma syndrome (OPPG). In some
other embodiments, the low bone mass phenotype disease can be
osteopenia or osteoporosis-pseudoglioma syndrome (OPPG).
[0186] Following administration of the compounds of the present
invention, systemic bone growth can be determined by a variety of
methods, such as improvements in bone density. Bone density can be
measured by a variety of different methods, including the T-score
and Z-score. The T-score is the number of standard deviations above
or below the mean for a healthy 30 year old adult of the same sex
as the patient. Low bone mass is characterized by a T-score of -1
to -2.15. Osteoporosis is characterized by a T-score less than
-2.15. The Z-score is the number of standard deviations above or
below the mean for the patient's age and sex. Improvement in the
T-score or Z-score indicate bone growth. Bone density can be
measured in a variety of places of the skeleton, such the spine or
the hip. One of skill in the art will appreciate that other methods
of determining bone density are useful in the present
invention.
[0187] The pharmaceutical compositions of the present invention can
be prepared for administration by a variety of different routes. In
general, the type of carrier is selected based on the mode of
administration. Pharmaceutical compositions can be formulated for
any appropriate manner of administration, including, for example,
topical, oral, nasal, intrathecal, rectal, vaginal, sublingual or
parenteral administration, including subcutaneous, intravenous,
intramuscular, intrasternal, intracavernous, intrameatal, or
intraurethral injection or infusion. A pharmaceutical composition
(e.g., for oral administration or delivery by injection) can be in
the form of a liquid (e.g., an elixir, syrup, solution, emulsion or
suspension). A liquid pharmaceutical composition may include, for
example, one or more of the following: sterile diluents such as
water for injection, saline solution, preferably physiological
saline, Ringer's solution, isotonic sodium chloride, fixed oils
that may serve as the solvent or suspending medium, polyethylene
glycols, glycerin, propylene glycol or other solvents;
antibacterial agents; antioxidants; chelating agents; buffers such
as acetates, citrates or phosphates and agents for the adjustment
of tonicity such as sodium chloride or dextrose. A parenteral
preparation can be enclosed in ampoules, disposable syringes or
multiple dose vials made of glass or plastic. The use of
physiological saline is preferred, and an injectable pharmaceutical
composition is preferably sterile.
[0188] The formulations of the invention are also suitable for
administration in all body spaces/cavities, including but not
limited to pleura, peritoneum, cranium, mediastinum, pericardium,
bursae or bursal, epidural, intrathecal, intraocular,
intra-articular, intra-discal, intra-medullary, perispinal,
etc.
[0189] Some slow release embodiments include polymeric substances
that are biodegradable and/or dissolve slowly. Such polymeric
substances include polyvinylpyrrolidone, low- and
medium-molecular-weight hydroxypropyl cellulose and hydroxypropyl
methylcellulose, cross-linked sodium carboxymethylcellulose,
carboxymethyl starch, potassium methacrylatedivinylbenzene
copolymer, polyvinyl alcohols, starches, starch derivatives,
microcrystalline cellulose, ethylcellulose, methylcellulose, and
cellulose derivatives, .beta.-cyclodextrin, poly(methyl vinyl
ethers/maleic anhydride), glucans, scierozlucans, mannans,
xanthans, alzinic acid and derivatives thereof, dextrin
derivatives, glyceryl monostearate, semisynthetic glycerides,
glyceryl palmitostearate, glyceryl behenate, polyvinylpyrrolidone,
gelatine, agnesium stearate, stearic acid, sodium stearate, talc,
sodium benzoate, boric acid, and colloidal silica.
[0190] Slow release agents of the invention may also include
adjuvants such as starch, pregelled starch, calcium phosphate
mannitol, lactose, saccharose, glucose, sorbitol, microcrystalline
cellulose, gelatin, polyvinylpyrrolidone, methylcellulose, starch
solution, ethylcellulose, arabic gum, tragacanth gum, magnesium
stearate, stearic acid, colloidal silica, glyceryl monostearate,
hydrogenated castor oil, waxes, and mono-, bi-, and trisubstituted
glycerides. Slow release agents may also be prepared as generally
described in WO94/06416.
[0191] In practicing the methods of the present invention, the
pharmaceutical compositions can be used alone, or in combination
with other therapeutic or diagnostic agents. The additional drugs
used in the combination protocols of the present invention can be
administered separately or one or more of the drugs used in the
combination protocols can be administered together, such as in an
admixture. Where one or more drugs are administered separately, the
timing and schedule of administration of each drug can vary. The
other therapeutic or diagnostic agents can be administered at the
same time as the compounds of the present invention, separately or
at different times.
VI. METHODS OF TREATING
[0192] In some embodiments, the present invention provides a method
of treating osteoporosis, wherein the method includes administering
to a subject in need thereof, a therapeutically effective amount of
a compound of Formula I.
[0193] The present invention also provides methods of treating
diseases characterized by secondary induced osteoporosis (low bone
mass) including, but not limited to, osteomalacia, polyostotic
fibrous dysplasia, Paget's disease, rheumatoid arthritis, zero
gravity, osteoarthritis, prolonged inactivity or immobility,
osteomyelitis, celiac disease, Crohn's disease, ulcerative colitis,
inflammatory bowl disease, gastrectomy, secondary induced
osteoporosis, amennorhea, Cushing's disease, Cushing's syndrome,
diabetes mellitus, diabetes, eating disorders, hyperparathyroidism,
hyperthyroidism, hyperprolactinemia, Kleinefelter syndrome, thyroid
disease, Turner syndrome, steroid induced osteoporosis, seizure or
depression induced osteoporosis, immobility, arthritis, cancer
induced secondary osteoporosis, gonadotropin-releasing hormone
agonists induced low bone mass, thyroid medication induced low bone
mass, dilantin (phenytoin), depakote induced low bone mass,
chemotherapy induced low bone mass, immunosuppressant induced low
bone mass, blood thinning agents induced low bone mass, Grave's
disease, juvenile rheumatoid arthritis, malabsorption syndromes,
anorexia nervosa, kidney disease, anticonvulsant treatment (e.g.,
for epilepsy), corticosteroid treatment (e.g., for rheumatoid
arthritis, asthma), Immunosuppressive treatment (e.g., for cancer),
inadequate nutrition (especially calcium, vitamin D), excessive
exercise leading to amenorrhea (absence of periods), smoking, and
alcohol abuse, pregnancy-associated osteoporosis, copper
deficiency, dibasic aminoaciduria type 2, Werner's syndrome,
Hajdu-Cheney syndrome, hyperostosis corticalis deformans juvenilis,
methylmalonic aciduria type 2, cystathionine beta-synthase
deficiency, exemestane, hyperimmunoglobulin E (IgE) syndrome,
Haemochromatosis, Singleton-Merten syndrome, beta thalassaemia
(homozygous), reflex sympathetic osteodystrophy, sarcoidosis,
Winchester syndrome, Hallermann-Streiff syndrome (HSS),
cyproterone, glycerol kinase deficiency, Bonnet-Dechaume-Blanc
syndrome, prednisolone, heparin, geroderma osteodysplastica, Torg
osteolysis syndrome, orchidectomy, Fabry's disease, pseudoprogeria
syndrome, Wolcott-Rallison syndrome, ankylosing spondylitis,
myeloma, systemic infantile hyalinosis, Albright's hereditary
osteodystrophy, autoimmune lymphoproliferative syndrome,
Brown-Sequard syndrome, Diamond-Blackfan anemia,
galactorrhoea-hyperprolactinaemia, gonadal dysgenesis, kidney
conditions, Menkes disease, menopause, neuritis, ovarian
insufficiency due to FSH resistance, familial ovarian
insufficiency, premature aging, primary biliary cirrhosis,
prolactinoma, familial prolactinoma, renal osteodystrophy,
ulcerative colitis, underweight, Werner syndrome, bone tumor, bone
cancer, brittle bone disease, osteogenesis imperfecta congenita,
and osteogenesis imperfecta tarda. Other conditions include a bone
injury, such as a fracture or weakened bone, or bone injured due to
radiation treatment. One of skill in the art will appreciate that
other types of conditions, diseases and treatments lead to
osteoporosis.
[0194] The present invention also provides methods of treating
patient populations characterized by injured bone, such as
fractured bone or bone injured due to radiation, as well as
children for whom osteoporosies medications are
contraindicated.
[0195] In some embodiments, the present invention provides a method
of promoting bone growth by administering to a subject in need
thereof a therapeutically effective amount of a compound of the
present invention.
[0196] Bone growth can be measured in a variety of ways known to
one of skill in the art. Methods of measuring bone growth include,
but are not limited to, Uct (micro CT), Dual X-ray absorption (Bone
density), ultrasound, QCT, SPA, DPA, DXR, SEXA, QUS, X-ray, using
the human eye during surgically manipulation, Alizarin red S, serum
osteocalcin, serum alkaline phosphatase, Serum bone Gla-protein
(BGP), bone mineral content, serum calcium, serum phosphorus,
tantalum markers, and serum IGF-1.
[0197] Many indicators of bone growth can be used to measure bone
growth, including bone density. In some embodiments, bone growth
can be demonstrated by an increase of 0.1% in bone density. In
other embodiments, bone growth can be demonstrated by an increase
of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 5, 10, 20, 30, 40,
50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 or
1000% or greater, in bone density.
[0198] One of skill in the art appreciates that bone growth be
local, systemic or both.
[0199] In some other embodiments, the method of the present
invention promotes bone growth by administering the compound of the
present invention, such as a compound of formula I. Administration
of a compound of the present invention can promote local bone
growth and/or systemic bone growth. In some embodiments, the
administration of a compound of the present invention promotes
systemic bone growth. Bone growth can be achieved by increasing
bone mineral content, increasing bone density and/or growth of new
bone. In other embodiments, local application of the compound of
the present invention and a drug achieves systemic bone growth.
[0200] In some other embodiments, the present invention provides a
method of treating low bone mass by administering to a subject in
need thereof a therapeutically effective amount of a compound of
the present invention.
VII. EXAMPLES
Example 1
Synthesis of LLP2A-Alendronate (LLP2A-Ale)
##STR00053##
[0202] LLP2A-Alendronate (LLP2A-Ale) is made by conjugate addition
of the sulfhydryl group of LLP2A-Lys(D-Cys) to
Alendronate-maleimide (Ale-Mal), the latter being prepared in situ
from alendronate and
sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(sulfo-SMCC). LLP2A-Lys(D-Cys) is prepared by solid phase synthesis
from several commercially available starting materials and one
characterized intermediate, 4-[(AP
-2-methylphenyl)ureido]phenylacetic acid (UPA), which was also
prepared from commercially available starting materials.
Synthesis of 4-[(N'-2-methylphenyl)ureido]phenylacetic acid
(UPA)
[0203] 4-[(N'-2-methylphenyl)ureido]phenylacetic acid (UPA) was
synthesized as outlined in FIG. 10A, Synthesis of UPA. In brief,
UPA was synthesized by adding o-Tolyl isocyanate (19.646 mL, 158.47
mmol) dropwise to a suspension of 4-aminophenylacetic acid (23.8 g,
156.9 mmol) in N,N-dimethylformamide (DMF) (62 mL) with stirring.
The mixture gradually became clear and was allowed to stir for 2
hours. The resulting solution was poured into ethyl acetate (700
mL) with stirring. The off-white precipitate was filtered and
washed with ethyl acetate (3.times.100 mL) and acetonitrile (ACN)
(3.times.100 mL), respectively. The solid was dried in vacuo.
Weight (off-white powder): 36.7 g (82.3% crude yield). Orbitrap
high resolution Electrospray Ionization Mass Spectrometry (ESI-MS)
[M+H].sup.+: 285.1197 (calculated: 285.1239), [M+Na].sup.+:
307.1010 (calculated: 307.1059), [M+K].sup.+: 323.0746 (calculated:
323.0798).
Solid Phase Synthesis of LLP2A-Lys(D-Cys)
[0204] LLP2A-Lys(D-Cys) was synthesized as outlined in FIG. 10B,
Solid phase synthesis of LLP2A-Lys(D-Cys).
[0205] Rink amide MBHA resin (0.5 g, 0.325 mmol, loading 0.65
mmol/g) was swollen in DMF for 3 hours before Fmoc-deprotection
with 20% 4-methylpiperidine in DMF twice (5 and 15 minutes,
respectively). The beads were then washed with DMF (3.times.10 mL),
methanol (MeOH) (3.times.10 mL) and DMF (3.times.10 mL),
respectively. Fmoc-Lys(Dde)-OH (0.519 g, 0.975 mmol) was dissolved
in a solution of N-Hydroxybenzotriazole (HOBt) (0.149 g, 0.975
mmol) and N,N'-diisopropylcarbidiimide (DIC) (152 uL, 0.975 mmol)
in DMF (8 mL), which was then added to the suspension of the beads.
The coupling was carried out at room temperature overnight. After
filtration, the beads were washed with DMF (3.times.10 mL), MeOH
(3.times.10 mL), and DMF (3.times.10 mL), respectively.
[0206] After removal of Fmoc, the beads were then subjected to two
cycles of coupling with and deprotection of the Fmoc-linker in the
same manner as described above. The beads were washed with DMF
(3.times.10 mL), MeOH (3.times.10 mL) and DMF (3.times.10 mL).
Fmoc-Ach-OH (0.365 g, 0.975 mmol) was dissolved in a solution of
HOBt (0.149 g, 0.975 mmol) and DIC (152 uL, 0.975 mmol) in DMF, and
was then added into the beads. The coupling was carried out at room
temperature for 2 hours. After filtration, the beads were washed
with DMF (3.times.10 mL), MeOH (3.times.10 mL), and DMF (3.times.10
mL), respectively. The Fmoc deprotection group was removed with 20%
4-methylpiperidine twice ((5 and 15 minutes, respectively)).
[0207] After washing with DMF, MeOH, and DMF respectively, the
beads were then subjected to additional coupling and deprotection
cycles stepwise with Fmoc-Aad(OtBu)-OH and Fmoc-Lys(Alloc)-OH in
the same manner as described above. After removal of Fmoc, a
solution of UPA (0.923 g, 3.25 mmol), HOBt (0.498 g, 3.25 mmol) and
DIC (509 .mu.L, 3.25 mmol) in DMF was added to the beads. The
reaction was conducted at room temperature until Kaiser test
negative (3 hours to overnight). The beads were washed with DMF
(3.times.10 mL), methanol (3.times.10 mL), and DMF (3.times.10 mL).
The Alloc protecting group was removed by treating with
Pd(PPh.sub.3).sub.4 (0.2 eq.) and PhSiH.sub.3 (20eq.) in
dichloromethane (DCM), twice (30 minutes, each).
[0208] A solution of trans-3-(3-pyridyl)acrylic acid (0.37 g, 1.3
mmol), HOBt (0.176 g, 1.3 mmol) and DIC (201 .mu.L, 1.3 mmol) in
DMF (8 mL) was added to the beads. The coupling proceeded at room
temperature 4 hours to overnight until Kaiser test was negative.
The beads were washed with DMF (5.times.5 mL), MeOH (3.times.5 mL)
and DCM (3.times.5 mL). The Dde protecting group was removed with
2% NH.sub.2NH.sub.2 in DMF twice (5 and 10 minutes, respectively).
The beads were washed with DMF, MeOH and DMF, followed by coupling
of (4 eq. to resin, 220 mg, 1.3 mmol) Boc-D-Cys(Trt)-OH, HOBt
(0.176 g, 1.3 mmol) and DIC (201 .mu.L, 1.3 mmol) in DMF (8 mL).
The coupling reaction was conducted at room temperature until
Kaiser test negative (4 hours to overnight). The beads were
thoroughly washed with DMF, MeOH and DCM, respectively, and then
dried under vacuum for 1 hour before adding a cleavage mixture of
82.5% trifluoroacetic acid (TFA):5% thioanisole:5% phenol:5%
water:2.5% triisopropylsilane (TIS) (v/v). The cleavage reaction
was conducted at room temperature over 2-3 hours. The off-white
crude product was precipitated out and washed with cold ether. The
purity was determined by analytical reverse phase high performance
liquid chromatography (RP-HPLC) and the crude product was used in
the next step without further purification. LLP2A-Lys(D-Cys)
MALDI-TOF MS [M+H].sup.+: 1502.88 (calculated: 1502.77);
[M+Na].sup.+: 1524.88 (calculated: 1524.75).
Synthesis of LLP2A-Ale
[0209] LLP2A-Ale was synthesized through conjugate addition of
LLP2A-Lys(D-Cys) to Ale-Mal, formed in situ from alendronate and
sulfo-SMCC. The synthetic scheme is shown in FIG. 10C, Preparation
of LLP2A-Ale through conjugating LLP2A-Lys(D-Cys) with Ale-Mal.
[0210] Alendronate disodium salt (1.0 eq.) (powder from
lyophilization of aqueous solution of alendronic acid and 2 eq.
NaOH) was dissolved in 0.1 M phosphate buffered saline (PBS) (with
10 mM ethylenediamine tetraacetic acid), pH7.5. The aqueous
solution was then cooled in an ice water bath, and a solution of
Sulfo-SMCC (1.1 eq.) in water was added dropwise. Following
completion of addition, the resulting solution was allowed to warm
to room temperature while being stirred for 2 hours. This solution
was cooled before the dropwise addition of a solution of
LLP2A-Lys(D-Cys) (1.0 eq.) in a small amount of 50%
acetonitrile/water. The pH was adjusted to between 6 and 7 with aq.
NaHCO.sub.3, if needed. The resulting mixture was allowed to warm
to room temperature and stirred for 1 hour or until Ellman test
negative, and then lyophilized. The resulting powder was
redissolved in a small amount of 50% ACN/water and purified by
RP-HPLC (C18 column). Buffer A: 0.5% acetic acid/H.sub.2O. Buffer
B: 0.5% acetic acid/ACN. The collected eluent was lyophilized to
give a white powder. The identity of LLP2A-Ale was confirmed with
Matrix-assisted laser desorption/ionization time of flight mass
spectrometry (MALDI-TOF MS)[M+H].sup.+: 1970.78 (calculated:
1970.88).
Example 2
Synthesis of LLP2A-Alendronate (1) [LLP2A-Ale (1)]
##STR00054##
[0212] LLP2A-Ale (1) was synthesized through conjugation of
Alendronate-SH (Ale-SH) to LLP2A-Mal via Michael addition. The
synthetic scheme is shown in FIG. 11.
[0213] Preparation 1a: Synthesis of Ale-SH. The synthesis of Ale-SH
was achieved by reacting alendronate with 2-IT (1 equivalent) in
PBS at pH 7.5 for 1 hour followed by precipitation with EtOH. The
solid was dissolved in water and precipitated with EtOH, twice.
[0214] Preparation 1b: Synthesis of LLP2A-Mal. LLP2A-Mal was
prepared with maleimide attached to the side chain of Lys and two
hydrophilic linkers between LLP2A and Lys(Mal) using similar
approach described above. The synthesis was performed on rink amide
MBHA resin by standard solid-phase peptide synthesis approach using
Fmoc/tBu chemistry and HOBt/DIC coupling. The synthetic scheme is
shown in FIG. 11. Fmoc-Lys(Dde)-OH was first coupled to the resin,
followed by coupling of two linkers. LLP2A was then prepared as
previously reported on the N-terminus of the linker using similar
approach described above. The Dde protecting group was removed with
2% NH.sub.2NH.sub.2 in DMF twice (5 min, 10 min). The beads were
washed with DMF, MeOH and DMF, followed by coupling of (3
equivalents to resin) 3-maleimido propionic acid and HOBt, DIC. The
coupling reaction was conducted at room temperature overnight. The
beads were thoroughly washed with DMF, MeOH and DCM and then dried
under vacuum for 1 hour before adding a cleavage mixture of 95%
TFA:2.5% water:2.5% TIS. Cleavage of compounds from the resin and
removal of protecting group were achieved simultaneously over 2
hours at room temperature. The off-white crude products were
precipitated with cold ether and purified by semi-preparative
reversed-phase high performance liquid chromatography (RP-HPLC) to
give LLP2A-Mal. The identity of LLP2A-Mal was confirmed by
MALDI-TOF MS [M+Na].sup.+: 1572.76 (calculated: 1549.78).
[0215] Preparation 1c: Synthesis of LLP2A-Ale (1). LLP2A-Ale (1)
was prepared by conjugating LLP2A-Mal with Ale-SH. Ale-SH was
dissolved in PBS buffer at pH 7.2 containing 5% DMSO. Subsequently,
a solution of LLP2A-Mal (1.2 equivalents) in a small amount of DMSO
was added to the Ale-SH solution. The resulting mixture was stirred
at room temperature for 1 hour and then lyophilized. The powder was
re-dissolved in a small amount of water and passed through Varian
MEGA BOND ELUT C18 column (60 mL, 40 um particle size) and eluted
with water, 5% ACN/water, 10% ACN/water and 50% ACN/water. The
eluents were collected and checked by mass spectroscopy. The
eluents with pure product were combined and lyophilized to give
white powder. MALDI-TOF MS [M+H]+: 1900.78 (calculated:
1899.83).
Example 3
Osteogenic Differentiation of Bone Marrow Stem Cells with a High
Affinity to LLP2A
[0216] A new color-encoding method that facilitates high-throughput
screening of OBOC combinatorial libraries was developed. This
method differs from the traditional methods used to monitor
integrin expressions in the MSCs, i.e., the use of antibody-based
fluorescence-activated cell sorting (FACS) or immunoblotting. In
the present method, polymer beads displaying chemical compounds or
families of compounds were stained with oil-based organic dyes that
are used as coding tags. The color dyes did not affect cell binding
to the compounds displayed on the surface of the beads. These
rainbow beads were prepared in a multiplex manner such that each
ligand reacted to one or a series of integrins that were coded one
color. See FIG. 7; see also, Luo, J., et al., J Comb Chem, 2008,
10(4): p. 599-604. This rainbow bead technique was then applied to
determine the integrin profile on the cell surfaces. By incubating
the bone marrow cells undergoing osteogenic differentiation with
the rainbow beads, we found that .alpha..sub.4.beta..sub.1 integrin
was highly expressed in these osteoprogenitor cells and had high
affinity to LLP2A as shown in FIG. 7.
[0217] In FIG. 7, bone marrow cells were cultured in osteogenic
medium for 7 days and incubated with rainbow beads. The purple
beads that coded with LLP2A, the ligand with high affinity and
specificity against .alpha.4.beta.1, were covered with layers of
cells identified by green arrows. Original magnification,
10.times., is shown on the right side of FIG. 7, and 20.times.
magnification is shown on the left side. Weak bindings were also
seen in the black, purple and green beads, coded RGD1, RGD2 and
LYK1 ligands respectively. All of these beads had non-specific
bindings to many other integrins.
Example 4
Human-MSCs Directed to Bone with LLP2A-Ale for Promoting Bone
Growth
[0218] Human MSCs (huMSCs) were obtained and injected together with
LLP2A-Ale to immunodeficienct mice, NOD/SCID/mucopolysaccharidosis
type VII (MPSVII). This mouse strain lacked the
.beta.-glucuronidase (GUSB) enzyme. The donor cells could be easily
detected using biochemical detection of .beta.-glucuronidase (See
Meyerrose, T. E., et al., Stem Cells, 2007. 25(1): p. 220-7;
Meyerrose, T. E., et al., Stem Cells, 2008. 26(7): p. 1713-22). At
three-month of age, the mice received a single intravenous (i.v.)
injection of either vehicle (100 .mu.l PBS/mouse), huMSCs
(5.times.10.sup.5/100 .mu.l/PBS/mouse), huMSCs+LLP2A (5 nM/mouse)
or huMSCs+LLP2A-Ale (500 ng/mouse; total compound weight 3.5 .mu.g,
with alendronate concentration of 500 ng/mouse). The alendronate
dose we used for the study was approximately one-fifth of the
therapeutic dose for the treatment of osteoporosis (See
Colon-Emeric, C. S., JAMA, 2006, 296(24): p. 2968-9; Ma, Y. L., et
al., Endocrinology, 2003. 144(5): p. 2008-15). As shown in FIG. 8,
LLP2A-Ale greatly increased the number of huMSCs on the bone
surface of huMSCs to bone as compared to the control groups (PBS
and huMSCs) 24 hours after the huMSCs injection. As shown in FIG.
1, three weeks after the transplantation, the huMSCs were only seen
adjacent to the bone surface in LLP2A-Ale treated group. HuMSC, as
shown by GUSB+ red stain, were only present at the trabecular bone
surface in the LLP2A-Ale-treated group (lower panel). There was no
demonstrable GUSB activity in the lung, liver, kidney and LVB that
received PBS (top panels) or huMSCs (middle panel). Cancellous bone
mass in the vertebral body was--more than 40% higher in the group
treated with MSC+LLP2A-Ale (cancellous bone volume, BV/TV
13.9.+-.2.2%) compared to PBS (BV/TV 9.4.+-.1.7%), MSC (BV/TV
10.2.+-.1.9%) or MSC+LLP2A (BV/TV 10.5.+-.0.5%) controls three
weeks after a single injection of huMSC and LLP2A-Ale. This
increase in cancellous bone mass was accompanied by significant
increases in biochemical bone formation parameters such as bone
formation markers, procollagen I N-terminal propeptide (P1NP), and
osteocalcin, see FIG. 2A, and surfaced-based bone formation
parameters such as osteoblast surface, mineral apposition rate or
surface-based bone formation rate (BFR/BS). See FIG. 2B-2C.
Osteoclastic resorption did not differ between the groups (CTX-1).
See FIG. 2A. As shown in FIG. 3A-B, bone formation rates at both
the endocortical and periosteal surfaces of the mid-femur also
increased by 50-100%, with markedly increased in intra-cortical
bone remodeling in huMSC+LLP2A-Ale treated group. These preliminary
data demonstrate that LLP2A-Ale can direct MSCs to bone to enhance
both cancellous and cortical bone formation and bone mass.
[0219] In FIG. 8, Three-month-old MSPVII mice received a single
intravenous injection of either of PBS, huMSC (5.times.10.sup.5) or
huMSC+LLP2A or LLP2A-Ale. The mice were sacrificed 24 hours later.
Following sacrifice, small portions of organ including lumbar
vertebral bodies (LVB) were harvested and frozen in Optimal Cutting
Temperature embedding media. The sections were stained using
naphthol-AS-BI-.beta.-Dglucuronide (GUSB) as a substrate.
Representative sections from lung, liver, kidney and lumbar
vertebral (LVB) trabecular bone regions were presented. Human MSCs,
as showed by GUSB+red stains, were seen accumulated in lung, liver
and kidney at 24-hours in huMSC, huMSC+LLP2A or huMSC+LLP2A-Ale
groups. Significant amount of these cells were also seen adjacent
to bone surface only in huMSCs+LLP2A-Ale group (lower panels).
Isolated GUSB-positive cells were also observed within bone marrow
of the LVB in MSC (middle panel) group.
[0220] NOD-SCID MPSVII Mice. The NOD-SCID MPSVII strain was the
result of extensive backcrossing of the mutant GUSB allele from the
B6.C--H-2.sup.bml/ByBirgus.sup.mps/+ mouse onto the NOD/LtSz-scid
background. Animals were bred and maintained at the Stem Cell
Department of the UC Davis Medical Center under approved animal
care protocols. Affected animals were generated by breeding mice
heterozygous for the MPSVII mutation. Homozygous GUSB-deficient
pups were identified at birth by biochemical analysis of toe
tissue.
[0221] Biochemical markers of bone turnover. Serum levels of the
amino terminal propeptide of type 1 procollagen (P1NP), osteocalcin
and C-terminal telopeptides of type I collagen (CTX-I) were
measured using mouse sandwich ELISA kits from Biomedical
Technologies (Stroughton, Mass.) or Immunodiagnostic System
(Fountain Hills, Ariz.). The manufacturer's protocols were followed
and all samples were assayed in duplicate. A standard curve was
generated from each kit and the absolute concentrations were
extrapolated from the standard curve. The coefficients of
variations (CVs) for inter-assay and intra-assay measurements were
less than 10% for all assays and are similar to the manufacturer's
references (Yao, W., et al., Arthritis Rheum, 2008, 58(6): p.
1674-86; Yao, W., et al., Arthritis Rheum, 2008, 58(11): p.
3485-3497).
Example 5
LLP2A-Ale Augmented Bone Formation and Bone Mass
[0222] Two-month-old female 129SvJ mice received intravenous (i.v.)
injections of vehicle (PBS), 2A (5 nM), Ale (250 ng/mouse) or
LLP2A-Ale [alendronate concentration of 10 ng/mouse (70 ng total
compound weight) or alendronate concentration of 250 ng/mouse (1.75
total compound weight)]. The dose of alendronate used for the
experiments were at least one-tenth lower than of the therapeutic
dose of alendronate for the treatment of osteoporosis (See
Colon-Emeric, C. S., JAMA, 2006, 296(24): p. 2968-9; Ma, Y. L., et
al., Endocrinology, 2003, 144(5): p. 2008-15). As shown in FIG. 9,
two days after the i.v. injections, LLP2A alone increased the
number of proliferating cell populations within the marrow cavity.
In contrast and as shown in FIG. 9, LLP2A-Ale increased these
proliferating cell populations adjacent to bone surface. In order
to monitor bone microarchitectural changes that resulted from the
treatments, repeated in vivo microCT of the distal femurs were
performed just prior to the first injections and after four weeks
when the mice were sacrificed. As shown in FIG. 4, compared to the
approximately 2-5% increase in cancellous bone mass in the PBS,
LLP2A, and Ale-treated groups, LLP2A-Ale, at higher dose level (250
ng), increased cancellous bone mass by nearly 20%. As shown in FIG.
4, trabecular thickness was increased in two dose levels compared
to the PBS-treated group. As shown in FIG. 5A-5C, LLP2A-Ale did not
change early osteoblast maturation (P1NP levels) but increased
osteoblast function (osteocalcin) with significant increases in
surface-based bone formation parameters including osteoblast
surface, mineral apposition rate and surface-based bone formation
rate at the distal femur metaphysis. As shown in FIG. 6, LLP2A
increased bone formation rate at both the endocortical and
periosteal surfaces of the mid-femurs (p>0.05). As shown in FIG.
6, LLP2A significantly increased bone formation rate at both the
endocortical and periosteal surfaces of the mid-femurs (p<0.05).
There were no dose-responses observed at the cortical bone
compartment.
[0223] In FIG. 9, two-month-old female 120SvJ mice received a
single intravenous injection of PBS, alendronate (500 ng/mouse),
LLP2A (5 nm/mouse) or LLP2A-Ale (10 ng or 500 ng/mouse). Mice were
sacrificed 48 hours after the treatment.
[0224] MicroCT. The right distal femur from each of the animals was
scanned using MicroCT (VivaCT 40, Scanco Medical, Bassersdorf,
Switzerland), with an isotropic resolution of 10 .mu.m in all three
spatial dimensions. The scan was initiated at the lateral
periosteal margin through the medial periosteal margin of the
distal femur and 0.1 mm from the highest part of the growth plate
continuing proximally for 2 mm. Mineralized bone was separated from
the bone marrow with a matching cube 3D segmentation algorithm. A
normalized index, trabecular bone volume/total volume (BV/TV), was
utilized to compare samples of varying size. Trabecular thickness
(Tb. Th), trabecular separation (Tb.Sp) and trabecular number
(Tb.N) were also calculated as described previously (Lane, N. E. et
al., J Bone Miner Res, 2006, 21(3): p. 466-76; Yao, W., et al.,
Arthritis Rheum, 2008, 58(6): p. 1674-86; Yao, W., et al.,
Arthritis Rheum, 2008, 58(11): p. 3485-3497).
[0225] Bone histomorphometry. After fixation in 4%
paraformaldehyde, the right distal femurs, mid-femurs and the
5.sup.th lumbar vertebral bodies were dehydrated in graded
concentrations of ethanol and xylene and embedded un-decalcified in
methyl methacrylate. The frontal sections (8 .mu.m thick) were cut
using a vertical bed microtome (Leica/Jung 2265) and affixed to
slides coated with a 2% gelatin solution. Unstained 8-.mu.m-thick
sections were used for assessing fluorochrome labeling and dynamic
changes in bone. Bone histomorphometry was performed using a
semi-automatic image analysis (Bioquant Image Analysis Corporation,
Nashville, Tenn.) linked to a microscope equipped with transmitted
and fluorescent light. Bone turnover measurements included single-
(sL.Pm) and double-labeled perimeter (dL.Pm), interlabel width
(Ir.L.Wi) and osteoclast surface. These indices were used to
calculate Mineralizing Surface (MS/BS) and mineral apposition rate
(MAR) and surface-based bone formation rate (BFR/BS) at the
trabecular, endocortical and periosteal surfaces (Lane, N. E., et
al., J Bone Miner Res, 2006, 21(3): p. 466-76; Yao, W., et al.,
Arthritis Rheum, 2008, 58(6): p. 1674-86; Yao, W., et al.,
Arthritis Rheum, 2008, 58(11): p. 3485-3497; Yao, W., et al., Bone,
1999. 25(6): p. 697-702).
[0226] Immunohistochemistry Staining. Bone samples were fixed in 4%
paraformaldehyde, decalcified in 10% EDTA for 10 days and embedded
in paraffin. Four-.mu.m sections were obtained and incubated in 3%
H.sub.2O.sub.2 in water to block endogenous peroxidases. Then the
slides were incubated with 1% normal donkey serum in PBS Tween 20
in PBS. Then the sections were incubated with the primary
antibodies. After blocking with peroxidase, the sections are
incubated with the secondary antibody for detection. Negative
control was included where primary antibody was omitted to
differentiate unspecific staining.
[0227] Histochemical Analyses of Enzyme Activity. Following
sacrifice, small portions of organs were harvested and frozen in
Optimal Cutting Temperature embedding media (Sakura, Torrance,
Calif.) and sectioned in 12 .mu.m thick slices. GUSB-specific
histochemical analysis was performed using
naphthol-AS-BI-.beta.-D-glucuronide (Sigma-Aldrich) as a substrate,
followed by counterstaining with methyl green.
[0228] Statistics. Statistical significance was assessed by
analysis of variance followed by Dunnett's post-hoc test for
comparisons between the treatment groups to the PBS vehicle control
group. P<0.05 was considered significant. All values are
expressed as means.+-.standard deviation.
[0229] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, one of skill in the art will appreciate that
certain changes and modifications may be practiced within the scope
of the appended claims. In addition, each reference provided herein
is incorporated by reference in its entirety to the same extent as
if each reference was individually incorporated by reference. Where
a conflict exists between the instant application and a reference
provided herein, the instant application shall dominate.
Sequence CWU 1
1
2014PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(2)..(2)alpha aminohexanedioic
acidMISC_FEATURE(4)..(4)hydroxyproline 1Leu Xaa Val
Xaa124PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)homoleucineMISC_FEATURE(2)..(2)alpha
aminohexanedioic acidMISC_FEATURE(4)..(4)alpha cyclohexylglycine
2Xaa Xaa Phe Xaa135PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)norleucineMISC_FEATURE(3)..(3)propargyl
glycineMISC_FEATURE(5)..(5)hydroxyproline 3Xaa Asp Xaa Gly Xaa1
544PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)cyclopropylalanineMISC_FEATURE(2)..(2)alpha
aminohexanedioic
acidMISC_FEATURE(3)..(3)1-aminocyclopropane-1-carboxylic
acidMISC_FEATURE(4)..(4)hydroxyproline 4Xaa Xaa Xaa
Xaa155PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)norleucineMISC_FEATURE(4)..(4)alpha
aminohexanedioic acidMISC_FEATURE(5)..(5)2-aminoindane-2-carboxylic
acid 5Xaa Asp Ala Xaa Xaa1 565PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)norleucineMISC_FEATURE(2)..(2)alpha
aminohexanedioic acidMISC_FEATURE(3)..(3)alpha
cyclohexylglycineMISC_FEATURE(4)..(4)hydroxyprolineMISC_FEATURE(5)..(5)al-
pha aminohexanedioic acid 6Xaa Xaa Xaa Xaa Xaa1 577PRTArtificial
SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)cyclopropylalanineMISC_FEATURE(2)..(2)alpha
aminohexanedioic acidMISC_FEATURE(3)..(3)alpha
cyclohexylglycineMISC_FEATURE(5)..(5)alpha aminohexanedioic
acidMISC_FEATURE(6)..(6)3-chlorophenylalanineMISC_FEATURE(7)..(7)alpha
aminohexanedioic acid 7Xaa Xaa Xaa Pro Xaa Xaa Xaa1
585PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)homoleucineMISC_FEATURE(2)..(2)alpha
aminohexanedioic
acidMISC_FEATURE(4)..(4)hydroxyprolineMISC_FEATURE(5)..(5)alpha
cyclohexylglycine 8Xaa Xaa Val Xaa Xaa1 595PRTArtificial
SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)norleucineMISC_FEATURE(3)..(3)phenylglycineM-
ISC_FEATURE(4)..(4)1-aminocyclopentane-1-carboxylic
acidMISC_FEATURE(5)..(5)alpha aminohexanedioic acid 9Xaa Glu Xaa
Xaa Xaa1 5104PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)1-aminocyclopentane-1-carboxylic
acidMISC_FEATURE(2)..(2)alpha aminohexanedioic
acidMISC_FEATURE(3)..(3)norleucineMISC_FEATURE(4)..(4)alpha
aminohexanedioic acid 10Xaa Xaa Xaa Xaa1114PRTArtificial
SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)cyclopropylalanineMISC_FEATURE(2)..(2)alpha--
aminohexanedioic
acidMISC_FEATURE(3)..(3)1-aminocyclopropane-1-carboxylic
acidMISC_FEATURE(4)..(4)alpha-aminohexanedioic acid 11Xaa Xaa Xaa
Xaa1124PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(2)..(2)alpha-aminohexanedioic
acidMISC_FEATURE(3)..(3)1-aminocyclopropane-1-carboxylic
acidMISC_FEATURE(4)..(4)alpha-aminohexanedioic acid 12Leu Xaa Xaa
Xaa1135PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)homoleucineMISC_FEATURE(5)..(5)alpha-cyclohe-
xylglycine 13Xaa Asp Ile Pro Xaa1 5146PRTArtificial
SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)cyclohexylalanineMISC_FEATURE(4)..(4)hydroxy-
prolineMISC_FEATURE(5)..(6)homocitrulline 14Xaa Asp Leu Xaa Xaa
Xaa1 5155PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)lysine 3-pyridine propionate
amideMISC_FEATURE(2)..(2)alpha-aminohexanedioic
acidMISC_FEATURE(3)..(3)norvalineMISC_FEATURE(4)..(5)hydroxyproline
15Xaa Xaa Xaa Xaa Xaa1 5165PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)norleucineMISC_FEATURE(4)..(5)hydroxyproline
16Xaa Asp Ile Xaa Xaa1 5176PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)homoleucineMISC_FEATURE(3)..(3)alpha-aminobu-
tyric
acidMISC_FEATURE(4)..(4)hydroxyprolineMISC_FEATURE(5)..(6)homocitrul-
line 17Xaa Glu Xaa Xaa Xaa Xaa1 5186PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)norleucineMISC_FEATURE(5)..(5)homocitrulline
18Xaa Asp Val Pro Xaa Gly1 5195PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)cyclohexylalanineMISC_FEATURE(2)..(2)alpha-a-
minohexanedioic acidMISC_FEATURE(4)..(4)2-amino-2-naphthylacetic
acidMISC_FEATURE(5)..(5)1-amino-1-(4-hydroxycyclohexyl) carboxylic
acid 19Xaa Xaa Val Xaa Xaa1 5204PRTArtificial SequenceSynthetic
ConstructMISC_FEATURE(1)..(1)homophenylalanineMISC_FEATURE(4)..(4)hydroxy-
proline 20Xaa Asp Ala Xaa1
* * * * *